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Fibre-based scaffolds are widely used in tendon/ligament tissue engineering; 
however there is still a need for an ideal scaffold that provides suitable mechanical 
properties along with biological signals required for tendon/ligament regeneration 
from mesenchymal stem cells.  
 
This study developed a novel biodegradable nano-microfibrous polymer scaffold 
by electrospinning PLGA nanofibers onto a knitted PLGA scaffold. This scaffold 
facilitated cell attachment and promoted bone marrow stromal cell (BMSC) 
proliferation, function and differentiation, performing better than knitted scaffolds that 
were seeded using a gel system (control). However, rapid biodegradation of the 
PLGA-based scaffold rendered it unsuitable for tendon/ligament repair. Hence, 
Bombyx mori silk, a biomaterial known for its high strength and very slow rate of 
biodegradation, was used to replace PLGA in the knitted scaffold design. 
 
Knitted silk scaffolds, using 3 yarns of silk fibers, were degummed using an 
optimized technique – boiling in 0.25% Na2CO3 solution along with detergent (0.25% 
SDS) and intermittent ultrasonic agitation – to improve sericin removal and to retain 
silk’s mechanical properties. The degummed scaffolds were placed on a rotating 
collector and coated with electrospun PLGA nanofibers, using an aqueous silk solution 
as glue. Seeding these flat hybrid nano-microfibrous scaffolds on both surfaces 
resulted in better cell attachment and subsequent proliferation as compared to single 
surface seeding. Rolling up the cell-seeded scaffolds after a week of culture produced 
 vii 
 
cylindrical constructs resembling a tendon/ligament graft, and also increased their 
failure load and stiffness. 
 
Versatility of electrospinning permits protein & cytokine incorporation within 
polymer nanofibres for sustained release. It was hypothesized that bFGF, when 
incorporated into and released from nanofibres over 1 week, would cause proliferation 
and differentiation of the seeded BMSCs. Polymeric nanoscaffolds capable of 
sustained release of bFGF, with different release profiles and surface properties, were 
fabricated using blending and electrospinning (Group I) and by coaxial electrospinning 
(Group II). When compared to Group II, Group I nanofibers were less hydrophobic 
and allowed a week-long sustained release of bFGF that was bioactive and stimulated 
tyrosine phosphorylation events in seeded BMSCs. Both scaffolds favoured cell 
proliferation. BMSCs lost their “stemness” after 2 weeks of culture on the Group I 
scaffolds. Upregulated expression of tendon/ligament-specific ECM proteins, 
increased collagen production and deposition indicated BMSC differentiation along 
the tendon/ligament fibroblastic lineage.  
 
Group I bFGF-delivering nanofibres were then coated over the optimised 
degummed knitted silk scaffolds to produce biohybrid nano-microscaffolds. The 
scaffolds showed better cell proliferation, with cells growing both on PLGA nanofibers 
and silk microfibers. The constructs showed upregulated gene expression of specific 
ECM proteins, manifesting as increased collagen production and improved mechanical 
properties. On the ECM-like biomimetic nano-architecture of nanofibers, sustained 
release of bFGF initially stimulated BMSC proliferation, and subsequently, their 
fibroblastic differentiation and a collagenous matrix deposition.  
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The novel scaffold system not only facilitated cell seeding and promoted cell 
proliferation, causing the resulting construct to be uniformly populated with cells, but 
also stimulated BMSC differentiation into a fibroblastic lineage, generating a 
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1 Chapter 1 
 




Tendons and ligaments are dense connective tissues that join muscle to bone and 
bone to bone respectively, transmitting tensile forces between them, providing 
mobility and stability to the joints. Injuries to tendons and ligaments are among the 
most common injuries to the body, representing about half of the 33 million 
musculoskeletal injuries occurring in the United States each year, and are particularly 
common in the young and physically active population (1). Associated with the 
problems of suboptimal healing and recurrent injury, these injuries are not only 
responsible for large health care costs, but also result in lost work time and individual 
morbidity (2, 3).  
 
While conservative management is associated with a high rate of re-rupture, 
surgical management with tendon grafts are essential for lacerated injuries and injuries 
associated with soft tissue damage, as well as those needing secondary or delayed 
repair. Despite many improvements in the currently available therapies involving 
autografts, allografts, and tendon/ligament prostheses, there remain significant 
limitations in our management of these conditions. Biological grafts have drawbacks 
like donor scarcity, donor-site morbidity, tissue rejection and disease transmission, 
while prosthetic devices have complications like wearing-out and poor long-term 
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performance. Tissue engineering holds promise in treating these conditions by 
replacing the injured tissue with an engineered tissue with similar mechanical and 
functional characteristics (4-13). 
 
A common approach in tissue engineering involves a three-dimensional porous 
biodegradable scaffold loaded with specific living cells and/or tissue-inducing factors 
to launch tissue regeneration or replacement in a natural way, with the scaffold 
eventually disappearing over a period of time (14, 15). Cardinal to achieve success 
with the tissue engineering approach is a scaffold that is biocompatible, biodegradable, 
porous and possesses an optimized architecture, sufficient surface area for cell 
attachment, growth and proliferation, favourable mechanical properties, and a suitable 
degradation rate (16-18).  
 
However, tissue engineering approaches have not been extensively studied for 
tendon/ligament regeneration because of difficulty in fabricating a scaffold possessing 
an optimized architecture to provide sufficient surface area for cell attachment, growth 
and proliferation, favourable mechanical properties and a suitable degradation profile 
(13, 19-21). 
 
Scaffolds for tendon/ligament tissue engineering have been made from braided or 
embroidered fabrics, but these often encounter problems of nutrient transmission and 
poor cell seeding efficiency (22-24). Knitted poly (lactide–co–glycolide)  (PLGA) 
scaffolds have been to shown to possess good mechanical strength and an 
interconnected porous structure for tissue growth; such scaffolds seeded with bone 
marrow stromal cells (BMSC) have been effectively used for tendon and ligament 
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tissue engineering (25, 26). However, this scaffold needed gel-systems such as fibrin 
or collagen gel for cell seeding, and was found to be unsuitable for ligament 
reconstruction in knee joint, as the cell-gel composite dissociated from the scaffold 
during motion. Gel systems are also likely to encounter nutrient transmission problems 
and cells seeded in a 3-dimensional gel are observed to proliferate more near the 
surface than in the centre of the gel (5, 27).  
 
Recently, “nanofibres” produced by electrospinning technology, from a variety of 
biodegradable polymers, have been applied for tissue engineering of bone, blood 
vessel and heart (28-33). These ultrafine electrospun fibers with sub-micron diameters 
possess a high surface area to volume ratio, and mimic the nanostructure of 
extracellular matrix (ECM) of natural tissue, and so can facilitate cell attachment, 
proliferation and ECM deposition. Various cell types including BMSCs have been 
grown successfully on nanofibers scaffolds in the form of non-woven mats and such 
cells have also been induced to differentiate along osteogenic, adipogenic and 
chondrogenic lineages (34-39). However, a nanofiber matrix alone would not be 
sufficiently strong for engineering fibrous connective tissues like tendon and ligament. 
A hybrid scaffold system that could combine the advantages of mechanical integrity of 
macrofibres and the huge biomimetic surface offered by nanofibers would be highly 
desirable in tendon/ligament tissue engineering.  
 
While PLGA-based scaffolds are expected to possess good biocompatibility to 
support cell attachment, growth and proliferation, the rather rapid hydrolytic 
biodegradation of these polyester scaffolds can result in complete loss of mechanical 
strength and integrity in several weeks to a few months (40), which is too short a 
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period to support a healing tendon or ligament. An alternative biomaterial that does not 
degrade as rapidly as PLGA would be better suitable for tendon/ligament tissue 
engineering. Silkworm silk possesses high strength and a very slow rate of 
biodegradation, and silk scaffolds can be expected to ensure a gradual transfer of load 
from the scaffold to the healing ligament/tendon over a period of 6 to 12 months (41). 
However silk in its native form is not biocompatible, and needs to be processed to 
render it biocompatible, taking care to retain its mechanical properties. 
 
Success of any tissue engineering approach also depends on the choice of optimal 
cell lines. The various cells that have been used for engineering tendons/ligaments are 
differentiated cells like fibroblasts derived from tendons/ligaments and dermal 
fibroblasts, and precursor cells like mesenchymal stem cells (23, 42). Using 
tendon/ligament-derived fibroblasts implies that one has to digest one mature 
tendon/ligament to create another. Mesenchymal stem cells (MSC), on the other hand, 
can be obtained by simple means from several tissues of the body like bone marrow or 
subcutaneous fat. Such cells also lack immunogenicity and this makes them an ideal 
candidate for use in allogenic implants (43-46). But when such stem cells are used to 
regenerate a tendon/ligament, the scaffold would need to be further idealized so that it 
also provides the adequate biological signals to encourage proliferation and 
differentiation of these seeded precursor cells into fibroblasts. Such a functional tissue 
engineering approach can produce an engineered tissue that is biomechanically, 
biochemically and histomorphologically similar to the normal tissue (9, 12, 20, 47, 
48). Apart from cyclic mechanical stimulation that can be applied though a mechanical 
bioreactor, fibroblastic differentiation can also be stimulated by specific growth and 
differentiation factors such as basic fibroblast growth factor (bFGF), TGFβ, EGF, 
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PDGF, GDF5 and IGF, which have been shown to improve tendon and ligament cell 
proliferation and matrix formation, both in vitro and in vivo (10, 49-51). However, 
delivering bioactive growth factors locally at the injury site in a sustained fashion has 
been a challenge, as most growth factors have an extremely small plasma half-life and 
are rapidly inactivated (52). 
 
Electrospinning offers the possibility to incorporate proteins like growth factors 
within the nanofibers (53-56). Such nanofibers could be used to reinforce a 
microfibrous knitted silk scaffold to produce a novel biofunctional nano-microscaffold 
capable of continuous local delivery of the incorporated growth factor at the target site, 
allowing proliferation and differentiation of the seeded precursor cells into fibroblasts, 
and subsequently regenerate an injured tendon/ligament. 
 
 
1.2 Literature Review 
 
1.2.1 Tendon and Ligament: Dense Connective Tissues 
 
Tendons and ligaments belong to a group of tissues termed as the dense 
connective tissues. Tendons connect skeletal muscles to bones and ligaments connect 
bones to bones (Figure 1.1), functioning primarily to transmit tensile loads between 
these structures and providing for the motion and stability of joints. Contraction of a 
muscle results in transmission of the load from the muscle, via its tendon, to a bone 
across a joint, resulting in movement of the bones around the joint. Thus, tendons 
operate to bring around movements of the joints, and ligaments prevent excessive 
movement of the joints and thereby provide stability. 
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Figure 1.1: Tendons of foot and ligaments of the knee joint are crucuial for joint 
mobility and stability 
 
 
1.2.2 Structure and Composition 
 
Being primarily mechanical in function, tendons and ligaments are composed 
predominantly of a fibrous matrix with relatively few cells. Tendons contain 86% 
collagen, 1–5% proteoglycans (PG) and 2% elastin measured by their dry weights 
(Table 1.1) and water constitutes about 60-80% of their wet weights. Collagen fibers 
are bundled together in a hierarchical fashion (Figure 1.2) within a matrix of 
glycosaminoglycans (GAG), which imparts these tissues with their excellent “fiber-
reinforced composite” like biomechanical properties (57). 
 
Collagen. The primary types of collagen present in tendons and ligaments are type I 
and type III collagen, which occur in a ratio of 3:1. Type I collagen is composed of two 
identical chains called α1(I) and a third called α2(I). Type III collagen is composed of 
three identical chains called α1(III) (58).  
 
Type I collagen fibers are arranged in a hierarchical fashion (Figure 1.2), wherein 
collagen polypeptides constitute the primary structure. Three polypeptides wind into a 
triple-helical collagen molecule. Collagen monomers, formed by cleavage of N- and 
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C-terminal polypeptides, are assembled into fibrils, which are then grouped in fibers. 
Adult human tendons have a bimodal distribution of collagen fibril diameters, with 
mean diameters of 60 and 175 nm (59). Collagen fibers are organized into roughly 
parallel bundles, nearly all the bundles being oriented along the longitudinal axis of the 
tendon; along with fibroblasts the bundles are grouped into fascicles. As compared 
with tendons, such bundles are shorter and less longitudinally oriented in ligaments. A 
crimp or banding pattern can be readily observed in histological preparations of 
collagen fascicles via polarized light microscopy. It has been observed that the crimp 
pattern disappears during the initial loading of a tendon, corresponding to the nonlinear 
‘‘toe region’’ in the stress-strain curve.  
 
 
Table 1.1: Extracellular matrix composition of tendons and ligaments (58) 
 
 
Non-collagenous ECM Proteins. There are several non-collagenous proteins present 




% dry wt. 
Characteristics or functions 
Type I collagen 80 Bundles of fibrils 
Type III collagen 5-15 Thin fibrils 
Type IV collagen, 
laminin, nidogen <5 
In basal laminae under epithelium 
and endothelium 
Types V, VI, and VII 
collagens <5 
VII forms anchoring fibrils; others 
unknown 
Elastin, fibrillin <5 Provides elasticity 
Fibronectin  <5 Associated with collagen fibers and cell surfaces 
Proteoglycans, 
hyaluronate 0.5 Provide resiliency 
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Leucine-Rich Proteoglycans (SLRPs; constituting of decorin, biglycan, fibromodulin 




Figure 1.2: Hierarchical structure of collagen in tendon (adapted from (60)) 
 
 
• Decorin is the predominant PG in the proximal/tensional regions of tendon (10). 
Recent studies have shown that glycosaminoglycans (GAGs) bound to decorin act 
like bridges between adjacent and contiguous collagen fibrils, regulating fibril 
diameter, suggesting their possible role in providing mechanical integrity to the 
tendon structure.  
• Biglycan plays a similar role, controlling collagen fibril diameter and modulating 
growth factor activity (61). It is predominantly found in the tensional regions of 
tendons/ligaments, along with aggrecan, a large aggregating PG (62-64). SLRPs 
are also involved in cell metabolism via binding to growth factors and in ECM 
organization via binding to various collagens, a process essential in development, 
tissue repair and metastasis. Their absence hinders the collagen assembly and 
 9 
 
results in an excessive number of very small collagen fibrils in tendons that 
decreases the tendon stiffness.  
• Tenascin-C (TN-C) is an ECM glycoprotein that is expressed only in the  normal  
myotendinous and osteotendinous junctions, but is expressed abundantly during 
embryogenesis and regeneration of musculoskeletal tissues (65, 66). TN-C 
provides elasticity for mesenchymal tissues subjected to heavy tensile loading, 
acting as an adaptor and modulator of cell-matrix interactions like cell adhesion 
and migration. It is upregulated in response to mechanical loading and also 
modulates growth factor activity (67). 
• Fibronectin, a heterodimeric glycoprotein that is rich in the Arg-Gly-Asp (RGD) 
tripeptide important for cellular adhesion via integrins, is also present in tendons, 
ligaments and other connective tissues. It also mediates posttranslational collagen 
fibril modifications and assembly (68). Fibroblasts cultured in vitro first express 
fibronectin, to help in cell attachment with the culture substrate, before producing 
collagen that can build up the ECM (69). 
 
Constituent cells of tendons and ligaments are fibroblasts arranged in longitudinal 
rows between bundles of collagen fibres. The cells constitute 20% of the tissue volume 
(21) and are responsible for the initial manufacture and then maintenance of the 
collagenous matrix during dynamic remodeling, which they do in response to load 
experienced and to some extent can contribute to healing. But, these cells are present at 
a relatively low density and possess low mitotic activity, resulting in a low turn-over 
rate of these tissues, which can also be partly attributed to the relatively low 
vascularity of these tissues (7, 70). Tendon/ligament fibroblasts do not possess any 
specific markers; while several groups have reported molecules like tenomodulin (71, 
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72) and scleraxis (73, 74) to be potential markers for tendons/ligaments, these proteins 
are also expressed in several other tissues like the eye (tenomodulin) and cartilage 
(scleraxis) (75). Therefore, tendons/ligaments are usually identified by their ECM: 
either by histological demonstration of dense collagenous bundles showing a crimp 
pattern, or by immunohistochemical or Reverse Transcriptase-mediated PCR (RT-
PCR) based demonstration of gene-expression of a combination of ECM molecules 
like collagen type I and III, tenascin-C, decorin, fibronectin and biglycan. 
 
Ligaments are morphologically and microscopically similar to tendons, but are 
metabolically more active. They possess a greater cell density, with cells having higher 
DNA content and also possess greater amounts of reducible cross-links between the 
collagen fibers in the ECM (76). 
 
1.2.3 Mechanical Properties and Testing 
 
Consistent with their primary function of transmitting uniaxial tensile loads across 
joints, tendons and ligaments are composed of axially-aligned collagen fibers, 
contributing to highly anisotropic material properties. Their mechanical properties are 
usually described in the axial direction as structural, material and viscoelastic 
properties (70). 
 
Structural properties (ultimate load, ultimate elongation, stiffness, and energy 
absorbed at failure) are extrinsic measures the overall structure of the tendon/ligament, 
and depend on their size and shape. These properties are obtained from load-
elongation curves after loading a tendon/ligament to failure (Figure 1.3A). On the 
other hand, material properties (ultimate tensile strength, ultimate strain, Young’s 
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modulus and strain energy density), are intrinsic measures of the quality of the tissue 
substance and are obtained from a stress-strain curve (Figure 1.3B). These values are 
independent of tendon/ligament shape and size, but vary according to the species and 
anatomical site of the tissue as well as the mechanical testing protocol and conditions. 
Tendons and ligaments typically possess an initial non-linear toe region of low 
stiffness (and modulus), which subsequently increases linearly as all muscle–tendon 
units get lengthened. 
 
 
A             B 




Adult mammalian limb tendons experience physiological loading of 10-70 MPa  
(most commonly 13 MPa; human Achilles tendon: 67 MPa) (77) and straining of 2–
5% (78). In vivo loads in general achieve no more than 10% of their ultimate force for 
ligaments and about 30-40% for tendons (Figure 1.4) (79). Young’s modulus differs 
substantially among various tendons (Table 1.2). 
 
Biological materials like tendons and ligaments also possess time- and history-
dependent viscoelastic properties due to complex interactions between the various 
tissue constituents, i.e. water, collagen, surrounding proteins and ground substances 
(80). The resulting phenomena of stress relaxation and creep play an important role in 
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determining the dimensional stability of these tissues. In addition, the nonlinear load-
elongation relationship also helps tendons to maintain smooth movement of joints 




Figure 1.4: In vivo forces in tendons and ligaments (79) 
 
 
Table 1.2: Mechanical properties of human tendons and ligaments (UTS: Ultimate 
Tensile Strength; Po: Ultimate Strain; E : Young’s modulus) (81-84) 
 
Tissue UTS (MPa) Po (%) E (MPa) 
Patellar Tendon 50-100 15-30 150-600 
Achilles Tendon 15-60 25-60 800-850 
Anterior Cruciate Ligament 13-46 10-40 150-300 
 
 
1.2.4 Tendon/Ligament Injury and Repair 
 
Tendon injuries can consist of tendinitis, which is an inflammation of the tendon, 
tendon laceration, or tendon rupture. Tendons, such as the patellar tendon of knee, the 
Achilles tendon of the foot and the flexor tendons of hand are frequently ruptured in 
young and active individuals, primarily during sports activities. Tendon/ligament 
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injuries are among the commonest injuries to the body, representing about half of all 
musculoskeletal injuries in the United States (1), with more than 100,000 patients 
undergoing reparative surgery (85). 
 
 
Figure 1.5: Correlation between the stress-strain curve of a tendon and its function; 
Stage I, the toe region where crimps get straightened, and Stage II, the linear elastic 
region are the regions of physiological functioning; Stage III is the stage of 
viscoelastic deformation, and Stage IV signifies rupture and failure (10) 
 
 
Tendons and ligaments are injured primarily by single impact macro-trauma or by 
repetitive exposure to low magnitude force. The Achilles tendon rupture generally 
results from a sudden large strain (more than about 8%, as shown in Figure 1.5) as in 
an explosive push-off maneuver or due to a direct blow to the tendon during 
contraction. Normal healthy individuals walk approximately 1–1.5 million strides per 
year; extensive physical activity causes in vivo repetitive loading of tendons in the 
lower limbs to induce damage that exceeds the regenerative ability of the tendons, 
resulting in overuse injuries (86).  
 
Healing Biology and Mechanics. Healing of injured tendons and ligaments has been 
found to be a long and complex process that is subjected to local and external 
influences. Generally, the process involves four overlapping but discrete phases:  
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(1) the hemorrhagic phase,  
(2) the acute inflammatory phase,  
(3) the repair or regenerative phase, and  
(4) the tissue remodeling phase (47, 70).  
 
Immediately post-injury, a hematoma is formed locally; within approximately 72 
hours, recruitment of acute inflammatory cells occurs, followed by fibroblasts leading 
to the deposition of a healing matrix consisting of an amorphous ground substance and 
randomly aligned collagen, predominantly thinner and shorter collagen type III (87). 
This is associated with a decrease, and often a reversal, in the ratio between collagen I 
and III (1:3). The repair and regenerative phase occurs from 48-72 hours until roughly 
6 weeks post-injury. The healed matrix becomes progressively more organized with 
time, although the collagen fibrils newly laid down by the fibroblasts remain relatively 
disorganized within the amorphous matrix. The remodeling phase, lasting up to one 
year or longer from the time of the initial injury is characterized by maturation and 
tissue remodeling of the healing matrix, during which the collagen ratio is restored and 
the collagen bundles get axially aligned. Nevertheless, the normal healing process in 
tendons is always associated with some scarring with the healed tendon never 
reacquiring its original strength, thus demonstrating the need for interventional 
treatment. 
 
The repair and remodeling phases are also accompanied by changes in the levels 
of cytokines and growth factors at the injured site. Notable is the upregulation of bFGF 
within the first week of injury, with a peak expression between days 7 to 9 (61, 88-90). 
Such upregulated expression of bFGF is also associated with a concurrent over-
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expression of FGF receptors; a significant upregulation in FGFR2 expression has been 
observed after 3 days of ligament transection, which fell to basal levels by 7 days (91). 
Other growth factors like Transforming Growth Factor (TGF-β1) and Platelet Derived 
Growth Factor (PDGF-BB) are also over-expressed following injury (92). Similarly, 
TGF-β receptors are also over-expressed along the repair site, peaking after 2 weeks 
and returning to basal values after 8 weeks post-injury (93). This shows that bFGF 
plays a role in the early phase and TGF-β1 in the later phases of tendon healing. 
 
Treatment Modalities. In the past, most of the treatment methods have been directed 
at surgical, pharmacological and rehabilitative techniques, aiming to improve the 
effectiveness of treatment and to expedite recovery. Currently, the main objective of 
treatment is to restore the injured tendon to normal length and strength. 
  
Conservative versus Operative: In recent years, athletes and young people seeking 
delayed treatment for an Achilles tendon rupture are usually treated operatively, 
whereas acute ruptures in non-athletes are treated conservatively or non-operatively. 
However, a very high incidence of re-rupture has been found in the non-surgical group 
when compared to patients who were treated surgically. Thus operative treatment may 
produce better functional results though with a higher risk of postoperative 
complications, whereas non-operative treatment may result in a suboptimal functional 
outcome (94). 
  
Biological Grafts: Ligament and tendon reconstruction started with the utilization of 
biological grafts. The current “gold standard” for surgical repair is to use autologous 
tendon. Tendon transfer has been found to be advantageous in the treatment of old, 
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unhealed ruptures or cases of re-rupture (70). However, one caveat is that during 
repair, the mechanical strength and structural characteristics of the host tissue are 
permanently altered. Moreover, several factors limit the extensive use of biological 
grafts: donor site morbidity, limited source, transmission of pathogens, and storage 
difficulties. 
 
Several biologic ECM based allografts and xenografts (Restore, CuffPatch, Graft 
Jacket, Permacol) have been available commercially. They have failure loads ranging 
from 38N to 239N (95), but have been reported to be unable to meet the biomechanical 
requirements of the original in vivo tendon (96). Moreover, these commercial products 
are derived from animal skin or intestinal mucosa, and usually encounter chronic 
inflammation and scarring after implantation (97) and are not the perfect treatment for 
tendon repair.  
   
Prostheses/Augmentation Devices: Devices using non-degradable polymers like 
Dacron, polytetrafluoroethylene, polypropylene or carbon fibers have been used as an 
alternative. But decades of experience have shown unsuccessful results in the long-
term. Most of these synthetic materials do not approximate the material properties of 
tendon or ligament, resulting in stress shielding in the natural tissue. Moreover, wear 
debris resulting in immunological reactions and degradation products resulting in 
acidification of the surrounding tissue, cell death or growth stasis, ultimately lead to 
implant failure necessitating additional surgery. In view of these problems, it was 
logical to consider biodegradable augmentation devices in combination with biological 




Tissue Engineering: An ideal treatment has yet to be defined as a long-term solution 
for tendon/ligament repair. The current demand for transplant organs and tissues far 
exceeds the supply, and increases in the aging population only serves to widen this gap 
further. Tissue engineering holds tremendous promise for creating alternatives to 
harvested tissues, implants, and prostheses.  
  
Tissue engineering has been defined as “an interdisciplinary field that applies the 
principles of engineering and the life sciences toward the development of biological 
substitutes that restore, maintain or improve tissue function” (4). Tissue engineering 
aims to achieve regeneration of tissues. Regeneration is a process that restores the 
normal structure, morphology and function of tissues, damaged by injury or disease, 
via partial recapitulation of tissue embryogenesis, thus differing from wound healing, 
which repairs damage with fibrous scar tissue. The inability of most human tissues to 
regenerate could be due to a lack of regeneration-competent cells, lack of an 
embryonic-like environment that favours regeneration over repair, the presence of 
factors in the wound environment inhibitory to regeneration, or some combination of 
the three. Because cells isolated from organs do not spontaneously reassemble into 
functional tissues, tissue engineering uses synthetic materials to help cells get properly 
organized. Recent advances in cell biology, nanotechnology, and computation have 
given new insights into critical processes by which physical cues in addition to 
chemical cues can regulate cell signaling and gene expression (98). 
 
There are two approaches in tissue engineering: (i) repair of small-scale injuries, 
such as damage to blood vessels or to walls of intestines, can be made by injecting 
individual patient or donor cells, or small aggregates of these cells, together with a 
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degradable scaffold directly into damaged tissue such that host cells are stimulated to 
promote local tissue repair; (ii) repair or replacement of more complex organs depends 
on growing tissues or organs in vitro by seeding synthetic scaffolds with patient or 
donor cells. There are four basic components in such a strategy: cells, scaffold, 




Figure 1.6: The basic approach to tissue engineering 
 
 
A. Cells: A key factor in the tissue-engineering approach to tissue repair and 
regeneration is the availability of appropriate cells. The presence of cells is crucial; this 
is because of their proliferation potential, cell-to-cell signaling, biomolecule 
production, and formation of extracellular matrix. The number of cells initially seeded 
strongly influence the nature of cell-mediated processes involved in tissue formation 
and the rate at which these developmental and physiological processes occur. It seems 
clear that some minimum threshold of the quantity of cells may be required at the 
repair site for normal neotissue formation.  The cells can be autogeneic, allogeneic or 
xenogeneic; they can be differentiated cells, stem or progenitor cells, or cells that have 
been genetically modified to make specific molecules (99). 
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B. Scaffolds: The role of the scaffold is to mimic the natural extra-cellular matrix in 
the engineered tissue. The constituent biomaterials and their biological inertness or 
biocompatibility, as well as the overall three-dimensional (3D) architecture of the 
scaffold are important factors that influence success of any tissue engineering strategy. 
Because of inherent difficulties associated with tissue grafts, several biodegradable 
polymeric systems have been used as materials for engineering load-bearing tissues. 
These include polyesters, polyanhydrides, poly(orthoesters), polyurethanes and 
polycarbonates, among others. According to the tissues to be engineered, scaffolds can 
be fabricated using various techniques, e.g., spongy and porous scaffolds for bone and 
cartilage tissue engineering can be obtained by particulate leaching or 3D printing 
techniques (17, 100, 101). An ideal scaffold should possess the following 
characteristics:  
i. biocompatibility; 
ii. biodegradability;  
iii. porosity; 
iv. sufficient surface area for cell attachment, growth and proliferation; 
v. biofunctionality to influence cell fate, and  
vi. a geometry that imparts the required mechanical properties. 
 
As new tissues generate, the cell-scaffold construct should closely simulate the 
mechanical properties of the natural tissue. 
 
C. Bioreactors: Currently there are two approaches to tissue engineering: one is to 
implant a cell–scaffold composite directly into the injured site, as such the body acts 
like a “bioreactor”; the other is to culture the cell-scaffold composite in a bioreactor, ex 
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vivo or in vitro, for a period of time before transplantation. The bioreactor allows 
controlled introduction of biochemical and physical regulatory signals to guide cell 
proliferation, differentiation and tissue development. A bioreactor-based approach 
allows better understanding of tissue development and the mechanisms of disease and 
offers several exciting prospects, such as off-the-shelf provision of essential 
transplantable tissue, and possible scale-up for commercial production of engineered 
tissues. 
  
D. Growth Factors: Growth factors are small polypeptides synthesized by a variety of 
cells of the immune and musculoskeletal system. By binding to specific cell surface 
receptors, growth factors trigger complex intracellular signal transduction pathways 
that stimulate the production of proteins involved in cell growth and proliferation that 
occurs both in normal and healing tissues. In physiological systems, several growth 
factors usually act in an orchestrated manner, and their relative concentrations, 
temporal and spatial distribution are often vital for the desired effect. 
  
E. Gene Therapy: Maintaining adequate concentration of growth factors at the injured 
site requires repeated applications during the healing process, necessitating 
development of delivery methods that prolong the effects of the growth factors. 
Studies using collagen and cellulose sponges as scaffolds have shown that these 
methods typically produce detectable levels of growth factors for only a few days. 
Gene transfer, a technique of delivering genetic material into target cells to alter their 
functions, can prolong the delivery of high concentrations of growth factors at the 
repair site, and their potential application to the field of ligament and tendon healing 
has recently begun to evolve (10). Gene silencing through RNA-intereference and 
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short-interfering RNA (siRNA) is another promising technique whereby expression of 
target genes can be decreased,  providing a valuable tool for promoting and directing 
the growth of functional tissues for tissue engineering applications (102). 
 
However, tissue engineering approaches have not been extensively studied for 
tendon and ligament regeneration perhaps because of the lack of 
 
i. sufficient knowledge about their cellular composition and function,  
ii. readily available autologous cell sources that do not cause donor site morbidity, 
iii. biomaterial scaffolds that can reproduce the microstructure and biomechanics 
of such tissues, and 
iv. advanced bioreactor systems capable of mechanically conditioning the 
engineered tissues (19).  
 
A more extensive study of the existing literature on tendon and ligament tissue 
engineering is presented in the next chapter, with particular focus on the challenges 
that the current project aims to address. 
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2 Chapter 2 
 





2.1 Tissue Engineering of Ligament and Tendon 
 
Decades of research have culminated in the understanding that successful 
engineering of a tissue like tendon/ligament would require the “functional tissue 
engineering” approach, using controlled restoration of tissue morphology and function 
to create a perfectly regenerated and functionally integrated tissue (20). This would 
need the use of optimal cell sources, ideal scaffolds, favorable environment of growth 




Although there is controversy about the identity and location of the cells 
responsible for collagen synthesis during tendon healing, it is currently thought that 
both intrinsic (tenocytes) and extrinsic cells such as the cells from tendon sheath 
contribute to tendon healing. However, questions remain about whether there is a 
sufficient pool of tenocytes or connective tissue progenitor cells to be recruited to the 





Cells used for tendon regeneration include fibroblasts from the skin, tendon or 
ligaments (6, 103, 104) and bone marrow stromal cells (25, 26, 42, 105-107). Bone 
Marrow Stromal Cells (BMSCs), also referred to as bone marrow mesenchymal stem 
cells, are a population of non-hematopoietic cells that can be isolated from bone 
marrow and that when re-introduced in vivo are capable of differentiating into cells of 
several lineages like bone, cartilage, ligament, tendon, fat, nerve and muscle (108-
110). BMSCs can be isolated from bone marrow aspirates, collected by a routine and 
relatively non-invasive procedure of needle biopsy. The protocol involves 
concentrating mononuclear cells by density gradient separation, followed by selective 
adherence of BMSCs to tissue culture polystyrene surfaces under low glucose and high 
serum containing culture conditions. 
 
The use of adult BMSCs neither possesses the dangers of immune rejection (as 
seen with allografts) no does it pose any ethical concerns that affect embryonic or fetal 
stem cells. In addition, BMSCs can also be genetically engineered by transfection with 
genes for growth factors. Autologous BMSC has been shown to significantly improve 
the structure and biomechanics of tendon after injury (105, 106). Constructs composed 
of allogeneic BMSC seeded on knitted PLGA scaffold with fibrin glue have also 
shown good potential for regeneration and repair of Achilles tendon (25) and ACL 
(26). In comparison with autogenous cells, use of allogeneic cells has various 
commercial advantages, including the ability to (i) produce large cell banks of 
scalable, stable and modifiable cells, (ii) mass produce ready-to-use implantable 







A scaffold should be made up of  biomaterials that are not only strong enough to 
support cells, but that also degrade at an appropriate rate, and provide specific 
biological signals influencing the seeded cells to behave in a certain way. Research in 
connective tissue engineering has currently been focused on using natural materials 
like collagen and bioresorbable polymers as a matrix into which cells are seeded. 
Biopolymers such as collagen, chitin and silk, and bioresorbable polymers like the 
poly(α-hydroxy acids) have been most commonly used in tendon and ligament repair. 
 
Use of animal-derived substances in medical products is often discouraged due to 
the potential risks of infectious pathogens and immunogenicity (111). Instead, 
synthetic poly(α-hydroxy acids) like PGA, PLA and their copolymer, PLGA could be 
used to fabricate mechanically strong and biodegradable porous scaffolds, possessing 
good biological compatibility, to suit the purpose. PLGA can be degraded completely, 
over a period of several weeks, by hydrolytic scission into biological metabolites (i.e., 
glycolic acid and lactic acid, respectively) and PLGA-based products have been 
approved for human use by the Food and Drug Administration (112). The poly(α-
hydroxy acids) offer several advantages over other materials with respect to design 
flexibility, controllable porosity and  degradation rate. PLGA has been used widely as 
surgical sutures and in many tissue-engineering applications. It can be fabricated into 
three-dimensional scaffolds of variable structure and porosity, having a wide range of 
mechanical and degradation properties. It has been observed that ACL cells and 
BMSCs adhere to and proliferate better on PLGA than on polycaprolactone (PCL), 




Tendons, being fibrous tissues, need fibrous scaffolds for optimal tissue 
engineering. Textile technologies can be used to fabricate woven or non-woven fabrics 
as scaffolds. Traditionally, braided and sometimes, embroidered or woven structures 
have been used for tendon tissue engineering (22, 23, 99). Knitted PLGA scaffolds 
(25, 26, 107) have high porosity and internal connective spaces as compared with a 
braided structure, especially when it is under tension. These spaces allow enough cells 
to be seeded initially and permit ECM to form and deposit therein during the repair 
process; this helps in functional integration of the engineered tissue into the 
surrounding tissues. Such knitted scaffolds have been coated with thin films of 
biomaterials like poly (ε-caprolactone) and type 1 collagen, in order to improve the 
mechanical properties and cell attachment and proliferation on the scaffolds. These 
coating techniques could modulate the mechanical properties and facilitate cell 
attachment and proliferation in the hybrid scaffold which could be applied with 
promise in tissue engineering of tendon/ligament (114). 
 
Scaffolding units of an engineered tissue should possess similar dimensions as the 
natural ECM. The fibers used in the knitted scaffolds are generally in the micrometer 
range, averaging 15-25 µm, which is far greater than the typical nanofibrous ECM 
proteins (collagen type I fibrils, 50-500 nm), that the synthetic polymers are supposed 
to emulate. Nanofibrous structures possess a high surface-to-volume ratio that 
improves cell adhesion, which consequently affects cell migration, proliferation, and 
differentiation. Three methods that have been used for the fabrication of nanofibrous 
scaffolds are phase separation (115, 116), self-assembly (117, 118) and electrospinning 
(14, 15, 29, 115, 116, 119-123). On a macroscopic scale, it has been suggested that 
pore shape, size, and interconnectivity are important for cell seeding, mass transport, 
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and three-dimensional tissue formation within a scaffold (14, 15). Electrospun fibers 
can form a porous nanostructure that closely mimics the natural ECM nanostructure 
(Figure 2.1).  
 
   
 
 A                     B 
Figure 2.1: Similarity between native ECM structure and electrospun polymeric 
nanofiber matrix; (A) Fibroblasts cultured on collagen fibrils of rat cornea [taken from 





Electrospinning is a process to easily produce polymeric fibers in the average 
diameter range of 100 nm to 5 mm, which are at least one or two orders of magnitude 
smaller than the fibers produced by conventional methods like melt or solution 
spinning. These fibers, most commonly referred to as “nanofibers”, or sometimes 
(though more correctly) as “submicron range” or “ultrafine” fibers, possess a high 
aspect ratio that leads to a large surface area. Electrospun fibers have been used in a 
wide variety of applications ranging from sensors, nanocomposites, filtration and 




A typical experimental setup of the electrospinning process consists of a syringe 
containing the polymer solution being charged by a high voltage DC supply connected 




Figure 2.2: A typical electrospinning Setup, comprising a high voltage power supply 
(HVPS), a syringe pump with a syringe containing the polymer solution and an Al-foil 
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A jet is ejected from the suspended liquid meniscus at the needle’s tip when the 
applied electric field strength overcomes the surface tension of the liquid. Near the 
critical point, where the electric field strength is about to overcome the surface tension 
of the fluid, the free surface of the suspended drop changes to a cone, also commonly 
referred to as the Taylor cone (Figure 2.3). As the electric field strength is increased, 
the jet is ejected from the surface of this Taylor cone and solidified polymer filaments 
are obtained on the grounded target as the jet dries. 
 
High-speed photography has demonstrated that the jet undergoes a series of 
electrically-driven whipping and bending leading to plastic stretching and formation of 
thin fibers. The resulting morphology and physical properties of the fiber depend on 
the fluid material properties: concentration, conductivity, dielectric permeability, 
dynamic viscosity, surface tension and density and on some operating parameters: flow 
rate, external electric field, electric current and distance between the needle and the 
target (126, 127). 
 
It is known that the fiber diameters can be decreased in electrospinning with lower 
polymer concentrations. The disadvantage is that this sometimes gives rise to the 
formation of beaded fibers. The tendency toward bead formation can be suppressed by 
specific additives that increase the conductivity of the solutions, without affecting their 
viscosity and surface tension (128). The list of electrospun materials includes synthetic 
polymers with a broad range of properties from non-conducting polyurethane to highly 





Electrospinning and Tissue Engineering 
 
Electrospinning has been used to fabricate scaffolds from a variety of 
biodegradable polymers, such as collagen (130-133), PCL (34, 36, 38, 39, 134-138), 
poly(d-lactide) (139), PLLA (140-142) and PLGA (120, 139, 141, 143, 144), for tissue 
engineering of tissues like bone, blood vessel and heart (28-33). 
 
Various cell types including bone marrow stromal cells have been grown 
successfully on nanofibrous scaffolds in the form of non-woven mats and such cells 
have also been induced to differentiate along osteogenic, adipogenic and chondrogenic 
lineages (34-39). The possibility of controlling the nanostructure and alignment of 
nanofibers and incorporating various proteins, drugs and DNA into the nanofibers adds 
promise to the application of electrospinning in tissue engineering (53, 54). 
 
A suitable scaffold for tendon/ligament tissue engineering, apart from providing 
large surface area, porosity and structural integrity, should also provide biological 
signals to encourage the proliferation and differentiation of the seeded precursor cells 
into tendon fibroblasts. Apart from cyclic mechanical stimulation applied though a 
bioreactor, tendinogenesis can also be stimulated by specific growth and 
differentiation factors (bFGF, TGF-β, etc). This is the principle behind functional 
tissue engineering of tendons, which aims to produce a tissue that is biomechanically, 
biochemically and histomorphologically similar to the normal tissue (47). Delivery of 
growth factor proteins from such biopolymer scaffolds can be prolonged, being driven 
by either passive diffusion or coupled to the rate of material degradation, both of 
which usually occur independently (111). Two parameters of protein release may thus 
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be adjusted: the magnitude of release can be varied by varying the amount of growth 
factor added to the matrix, and the kinetics of release can be varied by altering the 





Figure 2.4: Co-axial electrospinning Setup: “core-shell” structured nanofibers can be 
electrospun using two different solutions passing through two co-axial needles 




Coaxial electrospinning, a modification of the electrospinning technique using 
two concentric needles (Figure 2.4) has been used to spin two immiscible solutions 
into coaxial fibers (136, 145, 146). The fluids remain separate as they are charged and 
emitted from the nozzle, where after the “electrospinnable” solution in the outer tube 
forms a sheath around the inner core fluid (frequently a “non-electrospinnable” 
aqueous solution) and stabilizes it via suppressing the Rayleigh instability of the core 
fluid and reducing the surface tension forces of the core which causes it to break up 
into droplets. In an aqueous in vitro or in vivo environment, the aqueous pockets in the 







In order to tailor the differentiation of the BMSC-seeded scaffold constructs into 
tendons, specific extrinsic stimuli need to be applied. Though the exact environment or 
the cocktail of signals that can differentiate stem cells into tendon/ligament fibroblasts 
is still unknown, it has been shown that the appropriate cyclic mechanical stimulus 
promotes cell proliferation, organization, and extracellular matrix synthesis. It has 
been reported that the mechanical straining of BMSCs-embedded collagen gels 
resulted in upregulated expression of ligament fibroblast markers, significant cell 
alignment and density, formation of oriented collagen fibers in the ECM (35, 149), and 
improvement in mechanical properties, compared to non-exercised counterparts (104). 
While several mechanotransduction pathways have been postulated to explain the 
biological effects of mechanical signals on cells, growth factors are known to be an 
important mediator. It has been shown that mechanical loading induces increased 
expression and secretion of growth factors like TGF-β, PDGF and bFGF from tendon 
fibroblasts (150, 151). 
 
2.1.4  Growth Factors 
 
Several studies have tried to define the role of growth factors in tendon and 
ligament healing and determine appropriate strategies for the use of growth factors in 
engineering these tissues (6, 7, 152-154). Specific growth and differentiation factors 
like bFGF (or FGF-2), TGF-β, epidermal growth factor (EGF), PDGF, insulin-like 
growth factor (IGF), and growth and differentiation factor-5 have been shown to have 
the ability to improve tendon and ligament cells proliferation or matrix formation in 




During tendon development, several growth factors act in concert and their 
spatiotemporal pattern of expression plays a vital role in determining the outcome. 
Moreover, actions of certain growth factors like bFGF are exquisitely regulated 
because they can be inactive in normal tendons and become activated upon tissue 
injury or inflammation (155). Though the effects of individual growth factors have 
been studied in various in vitro and in vivo situations, little is known about the 
physiological levels and the complex interplay of the regulatory signals actually 
involved during tendon formation. This hinders attempts to further improve or enhance 




Figure 2.5: Structure of FGF-2 (156) 
 
 
bFGF belongs to a large family of structurally related heparin-binding molecules 
which mediate their action primarily through activation of high affinity transmembrane 
receptors. bFGF exists in various isoforms: the most commonly studied 18kD cytosolic 
isoform (Figure 2.5) and several higher molecular weight (22, 22.5, 24, 34kD) nuclear 
isoforms. It exhibits very high sequence homology (>90%) across a wide range of 





bFGF plays an important role in embryonic development and differentiation of 
various tissues, and also in angiogenesis, wound healing  and tissue repair (158-161). 
Tendon and ligament injuries are associated with a localized over-expression of bFGF 
within the first week, peaking at day 7 to 9 (61, 88-90),  as well as an over-expression 
of FGF receptors (FGFR2 upregulation between day 3 to 7) (91). Other growth factors 
like TGF-β1 and PDGF-BB are also over-expressed in the later phases of tendon 
healing (92, 93). In vitro, bFGF has been shown to result in increased proliferation, 
self-renewal and differentiation of multipotent and undifferentiated BMSCs into 
fibroblastic cells, specific for tendon and ligament lineages, exerting these effects at 
concentrations between 0.1-10 ng/mL (162, 163). However, when injected in solution 
into the body, the biological response is rapidly lost due to diffusional loss and/or 
enzymatic inactivation/degradation, with an effective plasma half-life of only 90 
seconds (164, 165); this illustrates the need for an advanced delivery system that can 
deliver the growth factor, in a bioactive form, continuously and locally at the healing 
site for optimal effects in tissue engineering applications. 
 
As previously mentioned, versatility of electrospinning technique offers a 
possibility of incorporating growth factors within polymer nanofibres, which could 
serve as a source for continued and controlled release of the growth factors (53-56, 
166). Such nanofibres when coated over a knitted scaffold can produce a nano-
microscaffold capable of continued release of the incorporated growth factor, 





2.1.5 Animal Models for Ligament/Tendon Injury and Repair 
 
Though in vitro cell culture assays and mechanical testing can provide key 
information about tissue-engineered products, experimental testing in an appropriate 
animal model would be essential for their critical evaluation and optimization. Factors 
that should be considered in assessing a potential model include the tissue type 
(ligament versus tendon and intrasynovial versus extrasynovial), the type of injury to 
be modeled (complete and incomplete tears as well as injuries with and without tissue 
gaps), the techniques of measuring the response to treatment, the ease of comparison to 
existing models and finally, the ease of translation to human trials and eventually to 
clinical usage (167, 168). 
 
New Zealand White Rabbits (NZWR) are commonly employed as animal models 
for tendon and ligament tissue engineering and are usually considered the lowest 
species suitable for most in vivo studies. Sufficient amount of autologous cells like 
bone marrow stem cells can be harvested from rabbits for fabricating a tissue-
engineered implant that could be implanted into the same rabbit (168, 169). Their 
anatomical features are also ideal for allowing implantation of the tissue engineered 
tendon/ligament. Rabbit patellar and Achilles tendons experience in vivo peak strains 
of 1-4% and peak forces of about 100N which is about 10-20% of their failure forces 
(11). Commonly employed polymer scaffolds are designed to sustain similar forces. 
Tendon repair ability in rabbits has been shown to be independent of their age (83). 
Though bone marrow volume and the resulting yield of BMSCs decrease with aging of 
rabbits, BMSCs from older rabbits nevertheless retain the same reparative abilities as 
those from younger rabbits (170). This would mean that separate studies using rabbits 
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2.2 Hypothesis, Objectives and Scope 
 
The aim of this PhD thesis is to develop a suitable scaffold for ligament/tendon 
tissue engineering. We hypothesize that a biohybrid scaffold that is sufficiently strong, 
while being porous, has a favorable nano-architecture for cell attachment and 
proliferation, is slowly biodegradable, and that can release bioactive regulatory 
molecules to seeded mesenchymal stem cells, would stimulate their proliferation and 
differentiation into fibroblasts of the ligament/tendon phenotype, and would be best 
suitable for ligament/tendon tissue engineering. 
 
Scaffolds developed in this research study are expected to be ultimately tested out 
on the rabbit patellar tendon model, where it would replace a full-thickness central-
third defect (1). While the failure load of a typical rabbit patellar tendon is around 180-
300N (171), it has been documented that peak forces generated in the tendon are 
usually around 100N (11). For the most vigorous activity, inclined hopping, tensile 
forces and stresses on rabbit tendons are within 30% of their ultimate force and stress 
values, respectively (172). If a scaffold was to replace one-third of the physiological 
function of natural tendon tissue, the load expected to be borne by the scaffold would 
be 20-33N. Taking safety factors and biodegradation into account, we envisage that the 
scaffolds developed in this study should be able to sustain a load of about 60-100N. 
 
The conventional in vitro tissue engineering approach has three components:  
 36 
 
(1) a scaffold that is seeded with (2) appropriate cells, and cultured in (3) an 
environment providing suitable chemical and biological signals to regenerate the tissue 
of interest.  
 
The approach proposed in this study aims to combine components from the 
environment, namely the biological regulatory molecules, into the scaffold so that a 
precursor cell seeded scaffold does not require any special culture media for in vitro 
tissue engineering. Such an approach would have greater relevance on in vivo 
implantation, where external supplementation with regulatory signals would not be 
possible without invasive measures, e.g., injection of growth factors into the healing 
site.  The proposed approach (Figure 2.6) would include three major components:  
 
(1) A biocompatible and biomechanically optimized scaffold, that is capable of 
releasing (2) a bioactive growth factor, locally and continuously over a prolonged 
period, so that (3) seeded precursor bone marrow stromal cells differentiate into 





Figure 2.6: Functional approach of tissue engineering a tendon using bone marrow 


















A novel biodegradable nano-microfibrous hybrid polymer scaffold would be 
developed by electrospinning nanofibers onto a knitted scaffold in order to provide a 
large bio-mimetic surface for cell attachment. It is expected that this technique would 
combine the superior mechanical strength and integrity of the knitted microfibres and 
the large surface area and better hydrophilicity of the nanofibers, thus facilitating cell 
attachment, new ECM deposition and tissue formation. A biohybrid nanofibrous 
scaffold system would be fabricated, using electrospinning technology, to allow 
prolonged and controlled release of bioactive basic fibroblast growth factor (bFGF) to 
stimulate proliferation and differentiation of seeded BMSCs into ligament/tendon 
fibroblasts. A biohybrid nano-microfibrous scaffold combining a mechanically strong 
knitted scaffold and the bFGF-releasing nanofibrous coating would then be fabricated 
and evaluated by in vitro studies for their efficacy in ligament/tendon repair. 
 
 





Thus the research project was planned to be conducted in four stages (Figure 2.7). 
In stage I, a PLGA-based hybrid scaffold system comprising of a knitted microfibrous 
scaffold coated with an electrospun nanofibrous matrix was conceptualized and 
fabricated. This hybrid nano-microscaffold was shown to be a potential scaffold for 
tendon and ligament tissue engineering. In stage II, a biopolymer, Bombyx mori silk, 
was evaluated to replace PLGA as the biomaterial to fabricate a knitted microfibrous 
scaffold that was biomechanically more suited for ligament/tendon regeneration. Stage 
III involved a development and optimization of bFGF-delivering PLGA nanofibres, 
and Stage IV evaluated the biomechanical and biological efficacy of the BMSC-seeded 
bFGF-releasing silk/PLGA-based biohybrid scaffold for ligament/tendon regeneration. 
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3 Chapter 3 
 
Stage I: Development of a Novel Nano-microscaffold for 
Tendon/Ligament Tissue Engineering 
 
 
A novel biodegradable nano-microfibrous polymer scaffold would be developed 
by coating electrospun PLGA nanofibers onto a knitted PLGA scaffold. A multipotent 
cell population of autologous BMSCs would be used to seed the scaffolds to evaluate 
efficacy for tendon/ligament regeneration. 
 
3.1 Materials and Methods 
3.1.1 Scaffold Fabrication 
 
Knitted scaffolds, of 20 mm x 40 mm dimension, were fabricated from PLGA 
(10:90 PLA:PGA; 3 yarns; 20 filaments/yarn; diameter of filament, 25 µm; Shanghai 
Tianqing Biomaterial Ltd. Co., Shanghai, China) fibers using a conventional knitting 
machine (Silver-Reed SK270, Suzhou Harisa Machinery, Suzhou, China; Figure 3.1). 
These scaffolds were kept uncurled on custom-made U-shaped stainless steel wire 
frames fabricated from 1mm diameter K-wires (Appendix B.2). 
 
Hybrid nano-microscaffolds were fabricated by electrospinning PLGA nanofibers 
onto the surfaces of the knitted scaffold. Briefly, a 25% (w/v) solution of PLGA (65:35 
PLA: PGA, Birmingham Polymers, Birmingham, AL) in a solvent mixture (1:1) of 
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Tetrahydrofuran (Tedia, Fairfield, OH) and N, N-Dimethylformamide (Sigma 
Chemicals, St. Louis, MO) was delivered at a rate of 0.10-0.20 ml/hr to a 18G stainless 
steel needle, maintained at a potential of 10-15 kV by a high voltage power supply unit 
(RR 30-2P/DDPM, Gamma High-Voltage Research, Ormond Beach, FL). Nanofibers 
were collected on the knitted scaffolds placed on a grounded aluminium foil, at a 
distance of 15 cm from the needle (Figure 2.2). After 1 hour, the scaffolds were turned 




Figure 3.1: Knitting machine used to fabricate knitted scaffolds from PLGA fibres; 
Inset: Bundle of PLGA yarn 
 
 
The scaffolds thus fabricated were characterized by phase-contrast inverted light 
microscopy, scanning electron microscopy (SEM) and in-vitro degradation and 
mechanical tests.  
 
3.1.2 Scaffold Morphology: Phase Contrast Microscopy and SEM 
 
Some nanofibres were collected on glass cover-slips and their diameter was 
measured by phase contrast microscopy (IX71 Inverted Research Microscope, 
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Olympus Optical, Hamburg, Germany) and using an image analysis software 
(MicroImage v4.5.1, Olympus). The nano-microscaffolds were sputter-coated with 
gold and their morphology observed by SEM (JSM-5800LV, JEOL, Tokyo, Japan). 
Diameter and pore size distribution of nanofibers was also measured from SEM 
images using the image analysis software. 
  
3.1.3 Degradation and Mechanical Testing 
 
Scaffolds were sterilized by exposure to formaldehyde gas. Hydrolytic 
degradation of the scaffolds was carried out in isotonic phosphate buffered saline 




Figure 3.2: Nano-microscaffolds (inset) being strained to failure on the Instron Tester 
 
 
Degradation was studied primarily by assessing the scaffolds’ mechanical 
properties, which is vital for functional replacement of tendons and ligaments. 




Tester, Instron, Norwood, MA) (Figure 3.2). Test-specimens of 20mm breadth and 
20mm gauge length were kept moist by spraying PBS and stretched to failure at a 
crosshead speed of 10 mm/min, without any pretension or preconditioning. The load 
(N) and extension (mm) were recorded, and the failure load, elastic-region stiffness 
and the toe-region stiffness were determined after plotting the load-displacement 
curves. 
  
3.1.4 Isolation and culture of Bone Marrow Stromal Cells (BMSC) 
 
BMSCs were harvested and cultured by previously described techniques (25). In 
brief, bone marrow was aspirated from the iliac crest of an anaesthetized 30 kg 
Yorkshire pig and mononuclear cells were concentrated by Ficoll gradient 
centrifugation and re-suspended in complete culture medium containing Dulbecco’s 
modified Eagle’s medium (DMEM) with low glucose (Gibco, Invitrogen, Carlsbad, 





                                A                    B 
 
Figure 3.3 A. BMSCs in second passage at nearly 100% conflency; B. Scaffolds 
freshly seeded with BMSCs: top row of nano-microscaffolds and bottom row of 






BMSCs were selected by their property of short-term adherence to tissue culture 
polystyrene, when incubated at 37°C with humidified 5% CO2. After 24 h, non-
adherent cells were discarded and adherent cells cultured, changing the medium every 
3 days. When culture flasks became nearly confluent after about 7 days (Figure 3.3A), 
the cells were detached and serially sub-cultured. Semi-confluent cells, obtained after 
sufficient expansion through three passages, were used for seeding scaffolds. 
 
3.1.5 Cell Seeding and Culture on Scaffolds 
 
Scaffolds were sterilized by exposure to formaldehyde gas and placed in the wells 
of a custom-made culture chamber (Appendix B.1). BMSCs were seeded at a density 
of 3.3 × 105 cells/scaffold. The nano-microscaffolds (Group I) were seeded by 
pipetting of 1ml of cell-medium suspension onto the scaffolds (Figure 3.3B). For 
control experiments, the knitted scaffolds (Group II) were seeded with BMSC 
suspended in 1ml of fibrin gel (Tisseel Kit Two-Component Fibrin Sealant, Baxter 
Healthcare, Deerfield, IL) using the manufacturer’s protocol. The two component 
solutions ‘A’ and ‘B’ were prepared separately: solution ‘A’ prepared by reconstituting 
lyophilised fibrin in aprotinin solution (3,000 KIU/ml), and mixing at 37°C; solution 
‘B’ by adding lyophilised thrombin to calcium chloride solution at 37°C. Cell pellets 
were mixed with both components of the fibrin sealant, in separate micropipettes, and 
were carefully coated onto the knitted scaffolds by pipetting equal amounts from each 
micropipette. When the two solutions are combined, the final stages of the clotting 
cascade were activated, and the fibrin sealant solidified and adhered to the scaffold 
rapidly without spilling. 
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The BMSC-seeded scaffolds were grown in vitro, in a 5% CO2 incubator at 37˚ C 
for 2 weeks, with the medium being replaced every 3 days. The “engineered tissues” 
were then assessed for cell attachment, proliferation, ECM synthesis, and mechanical 
properties on various time-points over the 2 weeks. 
  
3.1.6 Cell Seeding Efficiency and Cell Proliferation Assay 
 
After incubating the cell-seeded scaffolds (n=3; 2.5 x 105 cells/scaffold) for 36 
hours, the culture medium was collected from the wells into separate centrifuge tubes 
and cell count performed. The cell seeding efficiency was expressed as the number of 
cells attached to the scaffold as a percentage of the number of cells seeded. Scaffolds 
of each group were analyzed by a colorimetric metabolic assay for cell viability (MTS-
based, CellTiter 96 AQueous Assay, Promega, Madison, WI; Appendix B.3.1) on day 
2 and day 7. The absorbances of the culture media at 490nm were normalized to the 
average absorbance of group II scaffolds on day 2 to obtain the relative rates of cell 
proliferation in the scaffolds. 
 
3.1.7 Histology, Confocal and Electron Microscopy 
 
At the end of 1 week, scaffolds from both groups were assessed by inverted light 
microscopy after haematoxylin/eosin staining, by confocal laser scanning microscopy 
after live-cell staining with 5-chloromethylfluorescein diacetate (CMFDA; Appendix 




3.1.8 Collagen and Glycosaminoglycan Assays 
 
The total soluble collagen and sulphated glycosaminoglycan (GAG) synthesized 
and secreted into the culture medium was determined by using SirCol Assay for 
collagen and BlyScan Assay for GAG (Biocolor, Newtownabbey, Northern Ireland; 
Appendix B.5-6). Culture media were changed on day 5 and collected on day 7 to 
estimate the total amount of collagen/GAG secreted per scaffold in 2 days. 
 
3.1.9 RT-PCR Analysis of Gene Expression of ECM proteins 
 
Total RNA was extracted from both group of BMSC-seeded scaffolds on day 3, 
using Qiagen RNeasy Kit. The RNA extract was assessed for its purity and 
concentration by spectrophotometry and stored at -80°C. RT-PCR was performed for 
collagen I, tenascin C, decorin and biglycan, which are ECM proteins present 
relatively abundantly in tendons and ligaments. Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) was used as the house-keeping gene (149).  
 
Primer sequences (Table 3.1) were obtained from published literature (Collagen I, 
GAPDH (173); Tenascin C (174); Biglycan, Decorin (175)), and were synthesized by 
Research Biolabs, Singapore. After electrophoretic separation on 2% agarose gel, the 
RT-PCR products were photographed in a gel documentation system (Gel Doc 2000, 
BioRad, Hercules, CA) and densitometry analysis of the bands was performed with the 
help of imaging software (Quantity-One 4.4.0, BioRad). The average integrated 








Table 3.1: Primer sequences used in RT-PCR; 1: Forward primer; 2: Reverse primer; 
bp: base pairs; AT: Annealing Temperature; Cycles: number of PCR cycles  
 
Primer Sequence bp AT(°C) Cycles 
Collagen I 1 GAT CCT GCT GAC GTG GCC AT 2 ACT CGT GCA GCC GTC GTA GA 212 55 30 
Decorin 1 AGT GCG AAA GGC TGT GTT CA 2 GCG ATG CGG ATG TAG GAG AG 132 55 30 
Tenascin C 1 CAT CGT GAC AGA GGT GAC GGA AGA 2 GTG GCC ACC CTG GCG CTG ACA GGA 260 69 30 
Biglycan 1 GAG CCG CAC TTG GAC AAC A 2 AAG TCA TTG ACG CCC ACC TT 119 60 30 




3.1.10 Mechanical Testing of Cell-scaffold Constructs 
 
After 7 and 14 days of culture, mechanical tests were conducted on the cell-
scaffold constructs of both groups (n=4/5) as done previously for the unseeded 
scaffolds. The failure load, elastic-region stiffness and toe-region stiffness were 
determined. 
 
3.1.11 Statistical Analysis 
 
Data were analyzed by single-factor ANOVA and presented as mean ± standard 
deviation. For pair-wise comparisons, two-tailed, unpaired Student’s t-tests were used 






3.2.1 Scaffold Characterization 
 
The average thickness of the knitted scaffold varied between 0.6-1.0 mm and that 
of the nano-microscaffold was between 0.8-1.3 mm. Phase contrast microscopy 
(Figure 3.4A, Figure 3.5) and SEM (Figure 3.6) revealed that nanofibers with diameter 
varying from 300 to 900 nm were spread randomly over the surface and between the 
loops on the knitted scaffolds. The pores were interconnected with pore-size varying 
from 2 to 50 µm. 
 
   
   A                     B 
 
Figure 3.4: A. Smooth continuous PLGA nanofibers on a glass cover-slip (400X) 
B. Knitted scaffolds, before and after electrospinning PLGA nanofibers 
 
 
Mechanical testing revealed that the nano-microscaffolds had an initial failure 
load of 56.3 (± 6.66) N which fell to 1.82 (± 0.6) N by 14 days. The elastic stiffness 
and toe-region stiffness decreased from 5.80 (± 0.7) N/mm to 0.64 (± 0.2) N/mm and 




   
 A         B 
 
Figure 3.5: Phase contrast view of nano-microscaffold showing nanofibers 






Figure 3.6: SEM view of nano-microscaffold at showing nanofibers randomly 





Figure 3.7: Comparison of the failure loads for the virgin knitted PLGA scaffolds and 
nano-microscaffolds showing that the nano-microscaffolds possessed slightly lower 
failure loads than the virgin knitted scaffold 
 49 
 
3.2.2 Cell Seeding Efficiency 
 
The cell seeding efficiency was found to be 88.8 (± 1.11) % for the group I 
scaffolds, and 97.7 (± 2.02) % for fibrin-gel based delivery in group II scaffolds. 
 
 
3.2.3 Cell Morphology on Scaffolds 
 
BMSCs attached and grew well on the group I scaffolds, as evident in the phase-
contrast (Figure 3.8) and SEM images (Figure 3.9). On day 2, BMSC had attached to 
the nanofibers on the scaffold and had formed small cell-aggregates, which increased 
in size (day 7) and bridged across the scaffold connecting with other cell-aggregates 
(day 14). Abundant ECM was observed filling the pores between the nanofibers 
 
   
I       II 
 
Figure 3.8: Phase contrast microscopy of BMSC seeded (I) nano-microscaffold and 
(II) fibrin gel based knitted scaffold, after 3 days of culture 
 
  
 Hematoxylin and eosin staining (Figure 3.10) revealed that BMSC had a more 
elongated morphology in group I compared to group II scaffolds. Confocal microscopy 
(Figure 3.11) after fluorescent staining with CMFDA showed a more profuse cell 
proliferation in the group I scaffolds. 
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3.2.4 Cell Proliferation Assay 
 
Starting with the same number of cells (2.5 x 105) on both scaffold groups, MTS 
assay results (normalized to the average absorbance of group II scaffolds on day 2) 
gave values of 6.1 ± 1.03 and 11.7 ± 0.89 for group I, and 1.0 ± 0.28 and 1.2 ± 0.28 for 
group II scaffolds on day 2 and day 7 respectively. This shows that, between the 2nd 
and the 7th day, the cell-population increased by 92% in the group I scaffolds and by 
21% in the group II scaffolds (Figure 3.12). 
 
 






Figure 3.9: SEM images of nano-microscaffold and fibrin-based knitted scaffold 




3.2.5 Collagen and Glycosaminoglycan Assays 
 
Both group of BMSC-seeded scaffolds produced similar amounts of soluble 
collagen (Figure 3.13) and GAG (Figure 3.14). Group I scaffolds synthesized an 
average of 466.59 (± 179)µg of soluble collagen and 2.37 (± 0.2)µg of GAG between 
5th to 7th days of in vitro culture, whereas group II scaffolds synthesized 490.28 
(±556)µg of soluble collagen and 2.49 (± 0.6)µg of GAG during the same period, the 
differences being statistically insignificant (p > 0.05). 
 
 





Figure 3.10: H&E Staining of nano-microscaffold (left) and fibrin-based knitted 













               I (Nano-microscaffold)         II (Fibrin-based Knitted Scaffold) 




Figure 3.11: Confocal images after live cell staining showing a denser cell population 














Figure 3.12: Cell Proliferation assay showing that BMSCs proliferate more rapidly on 




      I (Nano-microscaffold)     II (Fibrin-based Scaffold) 
 
Figure 3.13: Similar total soluble collagen production by the BMSC-seeded scaffolds 




     I (Nano-microscaffold)     II (Fibrin-based Scaffold) 
 
Figure 3.14: Total soluble GAG production by the BMSC-seeded scaffolds between 
5th to 7th days of culture 
 
 
3.2.6 RT-PCR Analysis of ECM Proteins 
 
The concentration of RNA was determined to be 0.041 µg/µL from group II 
scaffolds (A260:280 = 1.182) and 0.080 µg/µL from group I scaffolds (A260:280 = 1.993). 
Gel-electrophoresis images proved that BMSCs growing on the nano-microscaffold 





Figure 3.15: Gel-electrophoresis image after separation of RT-PCR products 
 





Densiometric image analysis revealed that the mRNA expression for collagen-I, 




Figure 3.16: Densitometric analysis of RT-PCR data showing gene upregulation for 





3.2.7 Mechanical Tests 
 
Cell-seeded nano-microscaffolds, on days 7 and 14 of culture, possessed slightly 
higher values of failure load, elastic-region stiffness and toe-region stiffness than 
unseeded scaffolds maintained in PBS under similar conditions (37˚C, 5%CO2) for the 
same duration (Table 3.2). However, owing to small sample sizes (n = 4/5), the 
increase was not statistically significant for most comparisons. 
 







3.3.1 The nano-microfibrous scaffold geometry 
 
Though knitted scaffolds provide large 3D internal spaces for cell proliferation, 
nutrient and metabolic waste diffusion and for neovascularization after in vivo 
implantation, they require gel systems for cell seeding. These are often associated with 
problems of weak gel-scaffold attachment and poor nutrient transmission. Inspired by 
collagen type I nanofibrous architecture in natural extracellular matrix, non-woven 
scaffolds have been fabricated using nanofibers in the form of thin mats, which have 
proven useful in engineering of tissues like blood vessels, nerves and bones (28-33). 
However, for stronger tissues like tendon and ligament, a nanofiber scaffold alone 
would not provide sufficient strength. In the novel nano-microscaffold, fabricated by 
electrospinning PLGA nanofibers onto the surfaces of a knitted PLGA scaffold, the 
knitted microfibres provided the mechanical integrity while the nanofibers, randomly 
spread over the surface and between the loops of the knitted scaffold, increased the 
surface area and reduced the pore size of the scaffold. 
 
3.3.2 BMSC as candidate cells for tendon/ligament tissue engineering 
 
Tendon and ligament being relatively hypocellular tissues, it is difficult to obtain 
significant numbers of tendon/ligament cells for clinical tissue repair. BMSCs are 
known to possess the ability of self-renewal and differentiation into cells of various 
mesenchymal lineages. Their ease of collection and simplicity of isolation, and 
excellent properties of attachment, proliferation, and synthesis of an ECM rich in 
collagen type I make them suitable for tissue engineering applications (19). Several 
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studies have shown that BMSC could improve tendon healing (25, 106) and were 
better suited for ligament tissue engineering, than cells derived from ligaments or skin 
(23). RT-PCR results from this study indicated that BMSC retained the potential to 
differentiate along the lineage of tendon and ligament on the novel scaffold. 
 
3.3.3 Cell adhesion and proliferation on nanofibrous substrate 
 
In contrast to the tedious method of cell seeding using fibrin gel, nano-
microscaffolds could be easily and effectively seeded by the simple method of 
pipetting a cell-suspension onto them. The reduced pore-size (2-50 µm) of the scaffold 
and the large surface area to volume ratio of nanofibers facilitated cell attachment, 
proliferation and ECM deposition. BMSCs were seen to attach and proliferate well on 
the scaffold forming cell aggregates which gradually increased in size and fused with 
adjacent cell-aggregates to cover wide areas of the scaffold. Cell proliferation was 
better on the nano-microscaffolds than in the scaffolds seeded using fibrin gel, where 
cells would need to enzymatically digest the fibrin gel before they could proliferate 
(176). 
 
3.3.4 The effect of nanofibrous substrate on cell function 
 
The proliferating cells produced abundant ECM filling up the pores between the 
nanofibres. Collagen production by BMSC on the novel scaffold (466 µg/day 6 & 7) 
was higher than that produced by a similar number (3×105) of BMSCs grown on 
braided PLGA scaffolds (161µg/day 12) reported in a previous study (23). 
Furthermore, BMSCs on the nano-microscaffold exhibited a higher expression of 
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collagen-I, decorin and biglycan proving their potential to differentiate into tendon 
tissue. 
 
3.3.5 Limitations of the Study 
 
Due to the lack of current scientific knowledge about specific markers for 
tendon/ligament cells, this study relied on the expression of several non-specific 
tendon/ligament-related ECM proteins to characterize MSC differentiation into the 
tendon/ligament lineage. Also, research results such as RT-PCR could only be semi-
quantified. Quantitative or real-time PCR should be performed to obtain more reliable 
results. Though the study shows that BMSC-seeded novel scaffolds could differentiate 
into tendon/ligament lineage by synthesizing their major matrix, no specific attempt, in 
the form of biological or mechanical stimulation, was made to direct such 
differentiation. Moreover, the mechanical properties of the scaffold were not 
comparable to the normal values of tendon, with the constructs losing most of their 
strength after 2-3 weeks of culture. Use of knitted scaffolds with a different PLGA 
copolymer ratio, or with different biomaterials like PLLA or silk should be addressed 
to solve this problem in future studies. Nevertheless, this study exhibited the efficiency 
of this novel nanofiber-reinforced knitted scaffold for MSC delivery and synthesis of 
tendon matrix. It also suggested the new concept of nano-macrofibrous scaffold in 












A novel method for producing a nano-microscaffold was developed in this stage 
of the study.  
(i) Electrospinning nanofibres over the surface and between the loops of the 
knitted scaffold increased the surface area and reduced the pore-size of the 
knitted scaffold, thereby eliminating the need of cell-delivery by fibrin gel. 
(ii) Nanofibers, mimicking the natural nano-architecture of tendon/ligament 
extracellular matrix, promoted the capability of the bone marrow stromal cells 
to secrete a tendon/ligament specific ECM. 
(iii) The novel scaffold was shown to facilitate cell seeding, promote cell 




4 Chapter 4 
 






Successful tendon/ligament tissue engineering requires optimized structural 
scaffolds. While Stage I of the study demonstrated that the novel hybrid fibrous 
scaffolds combining PLGA nanofibres on knitted PLGA scaffolds improved the 
attachment, growth and proliferation of seeded cells, the rapid hydrolytic 
biodegradation of these scaffolds resulted in a complete loss of mechanical strength 
and integrity in 4 weeks (Figure 3.7), which is too short a period to support a healing 
tendon or ligament. An alternative biomaterial that does not degrade as rapidly as 
PLGA would be more suitable for tendon/ligament tissue engineering.  
  
We hypothesize that knitted scaffolds, made out of microfibrous silk fibres, would 
possess the advantages inherent to the knitted geometry of the scaffolds, while 
possessing superior mechanical strength and slower degradation rate, which are 
features of silk, and would thus be better suited for engineering tendons and ligaments. 
Unlike braided scaffolds that are usually too strong and stiff, leading to stress-
shielding and subsequent loss of mechanical properties (1, 178, 179) and unlike PLGA 
scaffolds that degrade too rapidly and fail to mechanically support the healing tendon 
beyond 4-8 weeks, a silk-based knitted scaffold would ensure an open porous 
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structure, possess an optimal strength (target value of 60-100N, in this study) while 
degrading slowly over 6-12 months, so that the healing tendon experiences the 
physiological stresses that accelerate its repair. However silk in its raw form is not 
biocompatible, so this chapter also presents a novel modification of the processing 
technique to render knitted silk scaffolds biocompatible. 
 
4.1.1 Silk as a Biomaterial for Scaffold Fabrication 
 
Silks are protein polymers that are spun into fibers by several Lepidoptera larvae 
such as silkworms, spiders, scorpions, mites and flies (180). The silk produced in form 
of cocoons by the mulberry-silkworm Bombyx mori is the most extensively used silk 
for various applications. While silk has been used in surgical sutures for decades, there 
has been a recent interest in them for use as tissue engineering scaffolds (180, 181). 
Their combined properties of high strength, toughness, flexibility and very slow rate of 
biodegradation that can ensure a gradual transfer of load from the scaffold to the 
healing ligament/tendon, are of particularly value in ligament/ tendon tissue 
engineering, where silk scaffolds have been extensively used (41). 
 
4.1.2 Structure of Silk 
 
A silk fibre obtained from a cocoon is generally about 800 meters long and 10-20 
μm in diameter, comprising a fibrous protein core covered by a coating protein called 
sericin that glues core proteins together (Figure 4.1).  
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Figure 4.1: SEM image [taken from (182)] and schematic depiction of cross section of 
a single native Bombyx mori silk fiber [adapted from (183)] 
 
The core protein consists of three chains: heavy chain, commonly referred as 
“fibroin” (MW: 350-390 KD), light chain (MW: 25 KD) and a glycoprotein, P25 
(184). Heavy and light chains are connected by disulphide bonds, while P25 is 
connected to both heavy and light chains by non-covalent interactions. Fibroin heavy 
chain is the fiber forming protein and its structure determines properties of the silk 
fiber; the light chain is necessary for secretion of the protein from the silk glands while 
P25 helps in assembly of heavy and light chains. 
 
94% of a fibroin chain are crystalline regions responsible for the secondary 
structure (antiparallel β-pleated sheets) of the protein, and interspaced amorphous 
regions act as linkers between the crystalline domains (185). Fibroin is composed 
mostly of hydrophobic amino acids, with 90% of the amino acid residues being 
glycine, alanine and serine. Hydrophobic nature of protein, significant crystallinity and 
extensive hydrogen bonding make fibroin insoluble in most solvents, including water, 
dilute acid or dilute alkaline solutions, and is also responsible for the protein’s 
elasticity (180). Sericin (MW: 20-310 KD) that contributes to 25-30% of the mass of 
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raw silk (181), on the other hand, comprises mostly hydrophilic amino acids, and 
dissolves easily in polar solvents, acids and alkalis, 
  
The natural spinning process of silk in the silkworm consists of a structural change 
in the protein from water-soluble random coils (silk I) in the glands to insoluble beta-
sheets (silk II) in the spun fibers. This transition of silk I to silk II involves formation 
of insoluble nuclei of β-strand crystals, which then grow rapidly forming aggregates of 
β sheets (186, 187). The liquid crystalline silk polymer is then concentrated in the silk 
ducts by removal of calcium salts and water, which is accomplished by a reduction in 
pH (188). Mechanical and frictional forces also act on the protein in the duct to control 
the protein folding and crystallization. Sericin forms a sheath around the fibroin core 
lowering the shear stresses and absorbing the water squeezed from the stretched fibroin 
mass during the process of fibre formation (189). Thus acidic pH, removal of calcium 
ions and water molecules along with the presence of external forces are responsible for 
the transition to silk II. 
 
4.1.3 Mechanical Properties and Degradation of Silk 
 
Apart from providing the initial framework for cells to attach and grow, tissue 
engineering scaffolds should also possess sufficient strength to withstand initial 
loading conditions. PLLA, a commonly used biomaterial for ligament/tendon tissue 
engineering scaffolds, has tensile strength lower than that of tendons and ligaments, 




Table 4.1: Comparison of mechanical properties of silk with several types of 
biomaterial fibers and tissues (180, 190) 
 
Material UTS (MPa) Modulus (GPa) Strain at break (%) 
B. mori silk 740 10 20 
Collagen X-linked 47-72 0.4 - 0.8 12 - 16 
PLLA 28-50 1.2 - 3.0 2 - 6 
Tendon 150 1.5 12 
 
The earlier thinking was that silk was non-degradable in vivo, having retained 
majority of its tensile strength beyond 2 months. However, silk is susceptible to 
proteolytic degradation, usually mediated by a foreign body response. In general, silk 
fibers lose the majority of their tensile strength within 1 year in vivo, and completely 
disappear from the implanted site by 2 years (180). However, the mechanical 
properties of silk also decrease when silk is immersed in an aqueous environment, with 
its wet-strength being about 75-85% of its dry-strength (191). This occurs due to 
weakening of hydrogen bonds present in the amorphous phase of the silk structure, and 
can be reversed by removal of the water molecules (192). 
 
4.1.4 Biocompatibility of Silk 
  
While natural biopolymers usually have superior biocompatibility, there were 
several concerns regarding the biocompatibility of Bombyx mori silk. Silk was known 
to cause type I allergic responses, which resulted in withdrawal of silk sutures from the 
market. Closer observation revealed that sericin was responsible for this sensitization 
and its removal and replacement, by a wax or silicone coating in commercial sutures, 
eliminated the allergic response (180). Thus while raw or virgin silk (fibroin 
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containing sericin gum) is a potential allergen, degummed silk after removal of sericin 
is biocompatible. 
 
4.1.5 Degumming Silk: Removal of Sericin 
  
Though fibroin is insoluble in most solvents, sericin can be dissolved in polar 
solvents, hydrolyzed in acids or alkalis, and degraded by proteases. Increasing the 
temperature further enhances its solubility in these solvents. This difference in 
solubility of the two proteins has been used to remove sericin, by a process which is 
termed “degumming”, to render the silk biocompatible. Commonly used methods use 
an aqueous solution containing a detergent and an alkaline salt, or enzymes (193). The 
conventional degumming protocol used in the textile industry involves boiling raw silk 
in 0.05-0.5% (w/v) Na2CO3 aqueous solution at 98~100oC for 30-90 minutes (193-
197), which removes the sericin through a combination of effects such as 
dispersion/solubilization and hydrolysis of the sericin polypeptides. Degumming 
results in a 30-40% reduction in the diameter of the silk fibers (182), which also 
become smooth and shiny. 
  
While conventional degumming techniques are adequate for silk cocoons, 
degumming of a 3-dimensional knitted structure is expected to be more difficult owing 
to the presence of knots and intersections of the bundles of silk fibers (189). The use of 
mechanical agitation, including ultrasonic vibrations, during the process of 
degumming has been suggested to improve the efficacy of enzymatic degumming 
methods (189). As degumming is also associated with loss of mechanical strength of 
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silk, it is essential that the process of degumming be optimized so as to remove sericin 
sufficiently while retaining the mechanical strength of the fibroin. 
 
4.1.6 Preparation of Aqueous Silk Solution 
 
Dilute aqueous salt solutions with an acidic pH cause the transition of silk I to silk 
II in the silkworm. Various solvents, that attain a reversal of these conditions, have 
been used to dissolve silk fibers into aqueous solutions: (1) 50% CaCl2 at 100°C, (2) 
ternary solvent containing CaCl2, ethanol and water at 60-90°C (198), and (3) 9M LiBr 
solution at 50-60°C or LiSCN solution at room temperature (195, 199-201). The silk-
salt solution is next dialyzed against deionized water for a period of 1-3 days to 
generate a pure silk solution. This regenerated silk protein has a heterogeneous 
structure, made up mainly of random coils, very similar to the helical silk I found in 
the glands. By increasing the silk concentration or by treating with solvents like 
methanol or ethanol, the regenerated silk protein can be induced to crystallize into β-
sheets thereby generating a silk II like structure (202-204). 
 
4.1.7 Regenerated Silk from Aqueous Silk Solution 
 
Aqueous silk solution can be processed by various methods like casting, freeze-
drying or electrospinning to produce solid scaffolds. Silk films can be produced by 
drying aqueous silk solutions at various temperatures. Overnight drying of a 2% 
aqueous silk solution in a 37°C incubator could produce a 30µm thick film, composed 
of type I silk (205). The fibroin structure in the films depend on the casting or drying 
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conditions: while casting at 100°C yields a completely amorphous structure, casting at 
room temperature results in α-helices, with some β-sheets; drying at 0 °C results in a 
lesser proportion of β-sheets (206). 
  
 This section of the study aims at developing a silk-based biohybrid scaffold 
that is biocompatible, sufficiently strong and has a degradation profile suited for 












Figure 4.2: Stages in fabrication of the hybrid scaffold system with PLGA nanofibers 





4.2 Knitted Silk Scaffold Fabrication: Optimization of Yarn Number 
 
4.2.1 Materials and Methods 
  
Scaffold Fabrication: Bombyx mori silk fibers (obtained from Mahasarakam 
University, Thailand) were knitted using the set-up described earlier, into 40 mm × 20 
mm scaffolds, with a setting of 12 needles and 27 strokes. Each yarn was composed of 
80 fibroin strands, each of an average diameter of 10µm. Raw silk fibers were used for 
knitting, as after degumming, the fibers separate into the 80 individual strands, which 
Knitting of Silk Scaffolds 
Optimized Degumming 
 
Adherent Coating with PLGA nanofibers 
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inevitably get entangled in the knitting machine, making knitting exceedingly difficult. 
To arrive at the desired failure load of about 60-100 N, scaffolds were knitted using 
either 3 (Group I) or 6 yarns (Group II) of the silk fibers.  
 
Scaffold Degumming and Characterization: The raw silk scaffolds were fitted onto 
the K-wire frames and degummed by the conventional method of boiling in a 
degumming solution of 0.25% Na2CO3 solution at 95-98˚C, with the medium being 
circulated by a magnetic stirrer (Figure 4.3A), and changed every 30 minutes. The 
process of degumming is associated with a change in colour of the scaffold from 
yellow to white, while the degumming solution turns yellow (Figure 4.3B). The end-
point of degumming was determined when the degumming solution stays clear and the 
scaffolds turn totally white indicating complete removal of sericin (191). 
 
   
Figure 4.3: (A) Degumming setup using agitation via magnetic stirrer on a hot plate; 
(B) sericin-rich yellow degumming solution after 30 minutes of degumming 
 
 
 The degummed scaffolds were characterized for the efficiency of degumming by 
observing for (i) completeness of sericin removal by SEM visualization, and (ii) 
retaining of mechanical strength of the knitted structure. The degummed silk scaffolds 
were sputter coated with gold and visualized by SEM at an accelerating voltage of 
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100kV. Mechanical testing (n=5, for each group) was carried out in an Instron Tester 
using the protocol mentioned earlier (Section 3.1.3). 
 
4.2.2 Results and Conclusion 
 
While the 3-yarn scaffolds were successfully degummed in 1.5 hours, the 6-yarn 
scaffolds required prolonged degumming for about 5 hours. Though the scaffolds 
appeared white macroscopically (Figure 4.4B), SEM observation revealed rough 
patched on the surface of fibers within the “knots” of the knitted structure of the Group 
I scaffolds, indicating the presence of traces of sericin (Figure 4.4C). 
 
 
   
Figure 4.4: Knitted silk scaffold before (A) and after (B) degumming; C shows 
retained sericin residues within a knot of the knitted scaffold 
  
 
Mechanical test results indicated that mechanical properties of the scaffolds 
deteriorated with extended degumming, which resulted in Group II scaffolds being 
significantly weaker than the Group I scaffolds (failure loads of 73N, group I; 22N, 





Figure 4.5: Tensile strength comparisons between 3-yarn and 6-yarn silk scaffolds 
after degumming 
 
The results from this study indicate that it was essential to optimize the 
degumming protocol for knitted scaffolds. Group I (3-yarn) scaffolds were chosen for 
subsequent studies because (i) they possessed a failure load within the desired range of 
60-100N, and (ii) the prolonged degumming required for Group II scaffolds made 
them weaker than Group I scaffolds. 
 
 
4.3 Optimization of Degumming Protocol 
 
 In order to minimize the loss of mechanical properties of the silk scaffolds, it is 
necessary to optimize the degumming process. This was achieved by modifying the 
degumming solution with an added surfactant (196) and introducing ultrasonic 
mechanical agitation of the scaffolds in the conventional chemical degumming 
method. The surfactant reduces surface tension at the water-silk surface and exerts a 
detergent-like effect, cleaning the sericin off the silk fibroin. 
 
mechincal strength of 














Mechanical Strength of 3 Yarns vs 6 Yarns 
Degummed Knitted Silk Scaffold 
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 The degumming agents and their concentration, and the total degumming time 
were kept constant, and the novel method was compared with the conventional method 
in terms of mechanical strength, microscopic structure, protein composition and cell 
proliferation.  
 
4.3.1 Materials and Methods 
 
Degumming of Scaffolds: To improve the degumming efficiency, a detergent sodium 
dodecyl sulphate (SDS) was added to the degumming solution, and ultrasound 
vibration applied to the scaffolds using a sonicator (KUDOS SK2500HP high 
frequency ultrasonic cleaner, KUDOS, Shanghai, China). Knitted scaffolds were 
boiled in 0.25% Na2CO3 solution with 1% SDS at 98~100ºC for 20 minutes, followed 
by sonication for 15 minutes in a sonicator bath at 70 ºC. The process was repeated, 
followed by 20 minutes of boiling in fresh degumming solution and rinsing with 
distilled water (Group A). As a control, another set of scaffolds were degummed, 
without using sonication, in 0.25% Na2CO3 with 1% SDS at 98~100ºC for 30 minutes, 
repeating the process with fresh degumming solution for another 60 minutes, followed 
by rinsing with distilled water (Group B). Thus the degumming duration was 90 
minutes for both groups. 
 
 Degummed scaffolds were evaluated for successful removal of sericin by SEM 
examination and polyacrylamide gel electrophoresis (PAGE), and by mechanical and 
degradation tests. Single silk fibers (comprising 80 fibroin strands) were also 




SEM of Degummed Scaffolds: Degummed silk scaffolds of both groups were sputter-
coated with gold and visualized by SEM, with attention being focused on fibers within 
the “knots” of the knitted structure, where sericin retention was a concern. Degummed 
single silk fibers were also visualized and compared. 
 
PAGE of Silk Proteins from Degummed Scaffolds: SDS-PAGE was conducted in 
order to qualitatively compare the protein composition in Group A and B scaffolds 
after the different degumming treatments. Degummed silk was dissolved in a ternary 
solvent system of CaCl2/ CH3CH2OH / H2O (1:2:8 molar ratio) at 70°C at a 10% (w/v) 
concentration. The solution was dialyzed (using a Pierce SnakeSkin pleated dialysis 
tubing with 10 KD molecular weight cut-off) against deionized water for a period of 
24-72 hours to generate a solution of silk proteins. Raw silk was dissolved in the 
solvent system and dialyzed to obtain a control for native silk proteins. The proteins 
were separated on a 5% polyacrylamide gel, stained with Coomassie brilliant blue or 
Silver stain, and visualized in a gel documentation system (Gel Doc 2000, BioRad, 
Hercules, CA). 
 
Mechanical and Degradation Tests: 18 scaffolds of each group were used for this 
study. Mechanical testing was carried out on 6 scaffolds of each group, immediately 
after fabrication (day 0), in a wet state, using the protocol described earlier (section 
1.1.3). The remaining scaffolds were kept in 1×PBS at 37ºC for 28 days, and 
mechanical tests conducted on day 14 and 28 (n=6) to observe any changes in their 




 Mechanical testing was also carried out on single fibers (comprising 80 fibroin 
strands) of raw silk and silk degummed using the two different methods. This is 
expected to provide a more accurate comparison of the effects of the two degumming 
methods on the mechanical properties of silk. The silk fiber was first mounted, using 
masking tape, onto a rectangular paper frame giving a gauge length of 40mm (Figure 
4.6). After mounting the frame with the silk fiber within the grips of a universal testing 
machine (Instron® 3345 Tester, Series IX and Merlin Software, Instron Corp., MA, 
USA), the side columns of the paper frame were cut and the samples (n=8) stretched to 
failure at room temperature. Load and extension were recorded and plotted. 
 
 
Figure 4.6: Schematic of a single silk fiber mounted on a rectangular paper frame; the 
big arrows indicate direction of application of strain 
 
 
Rabbit BMSC Isolation and Culture: Rabbit BMSCs were isolated and cultured by a 
previously established protocol (177), approved by the NUS Institutional Animal Care 
and Use Committee, National University of Singapore. In brief, bone marrow was 
aspirated from the iliac crest of anaesthetized New Zealand White Rabbits and 
collected into polypropylene tubes containing preservative-free heparin (1000 
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units/mL). The bone marrow was then diluted in an equal volume of culture medium 
containing DMEM-low glucose, L-glutamine, 110 mg/L Na-Pyruvate, Pyridoxine HCl 
(GIBCO, Invitrogen Corporation, CA, USA), 15% FBS, and plated into culture flasks. 
BMSCs were selected by their property of short-term adherence to tissue culture 
polystyrene, on incubation at 37°C with 5% humidified CO2. After 24 hours, non-
adherent cells were discarded and adherent cells cultured, changing the medium every 
3 days. When culture flasks became nearly confluent after about 7 days, the cells were 
detached and serially sub-cultured. Semi-confluent cells of second or third passage 
were used for cell seeding and biocompatibility experiments. 
 
Biocompatibility Evaluation of the Degummed Scaffolds: Nano-microscaffolds 
were fabricated from both groups of degummed knitted scaffolds, by coating them 
with electrospun PLGA nanofibres. A 5% (w/v) PLGA (PLA85:PGA15; Purac Asia 
Pacific, Singapore) solution in hexafluoro-2-propanol (HFIP; Fluka Chemie GmBH, 
Germany) was electrospun at 10-12kV and a flow-rate of 0.45 ml/hour onto the knitted 
scaffolds, placed on a collector, 15 cm from the positively-charged spinneret. Each 
surface was coated one after the other, and the hybrid scaffolds were seeded with 
BMSCs to qualitatively compare the efficiency of sericin removal.  
 
 Cell viability, proliferation and function, in terms of collagen production, were 
compared. Scaffolds were sterilized by exposure to formaldehyde gas, seeded with 1 
million rabbit BMSCs on each surface on alternate days, and cultured in complete 
media comprising DMEM-high glucose supplemented with 10% FBS and 1% 
antibiotics-antimycotics. At the end of 2 weeks, viable cells were stained using 
fluorescein diacetate (FDA, Molecular Probes, Invitrogen Corporation) and visualized 
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under the fluorescence microscope (details in Appendix B.4). Cell viability and 
proliferation over 3 weeks was studied by AlamarBlueTM dye reduction assay (details 
in Appendix B.3.2) by incubating the scaffolds in complete medium containing 5% 
AlamarBlue for 3 hours. Soluble collagen production by the cell-seeded scaffolds was 
estimated by Sircol® Collagen Assay at various time-points (day 3, 7, 14 and 21) over 
3 weeks of culture. 2 days’ old medium was collected from the scaffolds for 
determination of soluble collagen content. The cell-seeded scaffolds were also 
evaluated after 1 month of culture, for their mechanical properties using tensile tests, 




4.3.2 Results and Discussion 
 
 
SEM of Degummed Scaffolds: Group A scaffolds (degummed using sonication) 
demonstrated better sericin removal resulting in smoother fiber surfaces. Both single 
fibers (Figure 4.7) as well as fibers within the knots of the knitted scaffolds (Figure 
4.8) of Group B (degummed without sonication) showed presence of traces of sericin.  
 
   
Figure 4.7: SEM images of single fibers of raw silk (A) showing a thick sericin coat; 
traces of sericin could be observed on fibers degummed without sonication (B), while 
fibers degummed with sonication (C) were sericin-free and smooth. 
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Figure 4.8: SEM images of degummed scaffolds demonstrating smoother surface of 
fibroin in Group A (A,C) compared to Group B scaffolds (B,D), indicating a more 
complete removal of sericin on sonication 
 
 
PAGE of Silk Proteins from Degummed Scaffolds: PAGE results (Figure 4.9) 
showed that the native silk had components in both high and low molecular weight 
(MW) ranges. A dense band in the high MW region corresponding to the heavy chain 
of fibroin (350 KD) could be visualized. The same band is retained in the lane 
corresponding to silk degummed using the optimized method (Group A), but is lost 
and replaced by a smear with a lower molecular weight distribution in silk degummed 
using the conventional method (Group B). The optimized method is thus shown help 
preserve the integrity of fibroins, which is essential to maintain the mechanical 






Figure 4.9: SDS-PAGE showing better preserved high molecular weight fibroin heavy 
chains (white arrows) in Group A, while disintegration into a longer smear is observed 
after conventional degumming in Group B. Native silk also had a low molecular 
weight component, presumably sericin, which was lost after degumming in both 
groups 
 
Mechanical and Degradation Tests: Group A knitted scaffolds and single fibers 
degummed using the optimized technique were 32% and 38% stronger than their 
Group B counterparts (Figure 4.10 & Figure 4.11). There was no significant change in 
the stiffness of the scaffolds with degumming by either method. Group A scaffolds 
possessed almost similar failure load as the native silk scaffolds, though both groups of 
degummed single fibers were weaker than the native silk single fibers. This could be 
the result of the 90 minutes’ degumming that was appropriate for knitted scaffolds but 
was, most likely, excessive for single silk fibers. 
 
Failure load of the degummed scaffolds decreased after incubation in PBS at 37ºC, 
with a significant drop in the first 2 weeks, followed only a slight decrease over the 
subsequent 2 weeks. At all times, the Group A scaffolds exhibited higher failure loads 
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Figure 4.10: Group A scaffolds retained nearly similar failure loads as native silk 
scaffolds and were 32% stronger than Group B scaffolds 
 
 
Figure 4.11: Tensile testing of single silk fibers showing Group A fibers being 38% 





Figure 4.12: Mechanical properties of knitted silk scaffolds decreased in PBS, with a 
significant drop in failure load in the first 2 weeks; Group A scaffolds showed better 
mechanical properties throughout the duration of the study 
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Biocompatibility Evaluation of the Degummed Scaffolds: Both groups of scaffolds 
exhibited biocompatibility with cells attaching and proliferating, as shown by FDA 
staining and fluorescence microscopy (Figure 4.13). 
 
  
Figure 4.13: Fluoroscence microscopic images showing FDA-stained BMSCs growing 
on the nano-microscaffolds fabricated from Group A and B scaffolds (day 14) 
 
 
Alamar Blue assay revealed constantly increasing cell numbers over the 3 weeks 
of culture, with Group A showing a significantly larger cell population on day 21 




Figure 4.14: Alamar Blue assay showing constantly increasing BMSC numbers on the 
nano-microscaffolds over 3 weeks of culture, at the end of which Group A showed a 




 Sircol® Collagen assay during the first 2 weeks showed that a higher amount of 
total soluble collagen was produced from Group A scaffolds (2.0-2.5 mg/ scaffold) 
compared to Group B (0.7-1.6 mg/scaffold); however by the end  of the 3rd week, both 
scaffolds produced similar amounts (1.5-2.5mg/scAaffold). 
 
 Mechanical tests revealed that BMSC-seeded Group A scaffolds (64.5 ± 5.72 N) 
were over 41% stronger than their Group B counterparts (45.7 ± 10.97 N), after 1 
month of culture (p<0.01). Both groups of scaffolds possessed similar linear stiffness 
(4.3 N/mm). It was noted that cell-seeded scaffolds were stronger than their unseeded 
counterparts that had been soaked in culture medium for a similar duration. The 
increase in strength was more prominent with the Group A scaffolds (64.5 N, 
compared to 54.8 N without cells).  
 
 From this study, it can be concluded that the novel method of degumming 
improved sericin removal, preserved fibroin structure and mechanical properties of the 
resulting scaffolds that were biocompatible and allowed better proliferation of the 
seeded BMSCs, which in turn produced more collagen and resulted in stronger cell-
seeded scaffolds.  
 
 However it was observed that the bonding between the PLGA nanofibers and the 
knitted silk scaffolds was not strong and that the nanofibrous layer could be peeled off 
(Figure 4.15). This problem was not encountered in the Stage I of the study, where 
hybrid scaffolds were fabricated from the same polymer, using knitted PLGA scaffolds 
and PLGA nanofibers. In the next subsection, the fabrication of hybrid scaffolds was 




Figure 4.15: Poor bonding between nanofibrous PLGA layer and the underlying 
knitted silk microfibrous scaffold 
  
 
4.4 Fabrication and Optimization of Hybrid Scaffolds 
 
 Optimzation of the hybrid scaffold was  performed on three aspects. 
 
(1) To improve bonding between the PLGA nanofibre layer and the knitted silk 
microfibers, two modifications were devised: 
i. an aqueous silk solution would be used to coat the knitted silk scaffold, 
immediately prior to electrospinning. This would act as a glue between the 
nanofibre layer and the knitted scaffold. The effect of the silk film, formed by 
drying of the silk solution around the knitted silk scaffold, on the mechanical 
properties of the scaffold and the stability of the film were studied. 
ii. the knitted scaffold would be attached onto a rotating collector to allow 
nanofibers to wrap around the knitted scaffold and uniformly coat both 
surfaces. 
   
(2) The protocol for seeding cells on the hybrid scaffold was improved by seeding both 
surfaces of the scaffold on successive days, instead of just one surface.  
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(3) Since tendon and ligaments aimed to be repaired by the tissue engineered construct 
developed in this study are cylindrical in structure, the flat rectangular cell-seeded 
scaffold was rolled up into a cylindrical construct. Mechanical properties of knitted 
scaffolds in flat and rolled geometries were compared, and cell proliferation in both 
geometries of the hybrid scaffolds were also studied and compared. 
 
 
4.4.1 Materials and Methods 
 
Fabrication of Hybrid Scaffolds: The degummed knitted silk scaffolds were mounted 
on rotating frames of a collector connected to a battery-operated motor (Figure 4.16A). 
The corners of the scaffolds were sewed to the steel frame using degummed silk fibers 
as sutures. Such an arrangement allowed about 12 scaffolds to be simultaneously 
coated with nanofibers; the hybrid scaffolds could be released from the frames by 
simply cutting off the silk sutures. Each scaffold was coated with 1ml of 2% aqueous 
silk solution (prepared as described earlier in Section 4.3.1), by pipetting the solution 
onto the scaffolds. 
 
  




Knitted Silk Scaffold Electrospinning Nozzle Silk-PLGA Nano-microscaffold 
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 The scaffolds were next coated with nanofibres produced from a blend of 6.1% 
(w/v) PLGA (PLA85:PGA15; Purac) solution in HFIP and 0.1% BSA (Bovine Serum 
Albumin) in 100mM TRIS (pH 7.2), by electrospinning at 10-12kV and a flow-rate of 
0.45 ml/hour onto the scaffolds, rotating at 60 rpm on the collector, 15 cm from the 
positively-charged spinneret (Figure 4.16B). The above composition yields a final 
PLGA concentration of 5% (w/v) in the blend; such blend-nanofibres were used as the 
study aims to ultimately generate protein-releasing nanofibres, which will be described 
in the next chapter.  
 
Study of the Effect of the Silk Solution on Knitted Silk Scaffolds: While coating the 
knitted scaffold with silk solution before electrospinning could help in better adhesion 
of the nanofibers, the stability of the silk film formed by drying of the solution, and its 
effect on the mechanical properties of the knitted scaffold, are not known. To address 
these concerns, a series of short studies were conducted: 
 
 (i) Silk films were created by drying the silk solutions on a glass cover slip, and their 
stability in water was observed over 3 days; 
 
(ii) Knitted silk scaffolds coated with the silk solution were dried, and then soaked in 
culture media (DMEM with 5% FBS) for 7 days. The total protein content of the 
media was determined before and after the process, by Biorad Protein Assay, to 
determine if proteins were eluted from the scaffold into the culture medium; 
 
(iii) Knitted scaffolds coated with silk solution and dried were evaluated for their 
mechanical properties by tensile tests. Before tensile testing, the scaffolds were rolled 
up and their diameter measured at 3 different points along the length of the scaffold, 
using a digital micrometer, and averaged to calculate the cross-sectional area 
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(assuming a circular cross-section). Tests were also conducted after soaking these 
scaffolds for 1 and 3 days in culture medium, and also on uncoated and un-soaked 
knitted scaffolds as controls (n=5). 
 
Cell Seeding Protocol Optimization: The hybrid scaffolds in the earlier stages of the 
study were seeded only on a single surface. It was hypothesized that seeding both 
surfaces on successive days would improve cell proliferation and distribution within 
the scaffold. 8 hybrid scaffolds were used in this study. 4 scaffolds (“2M1”) were 
seeded with 2 million rabbit BMSCs on one surface, and the other 4 (“1M2”) were 
seeded with 1 million cells on one surface and 1 million cells on the other surface on 
the subsequent day. Scaffolds were cultured in DMEM supplemented with 10% FBS 
and 1% antibiotics-antimycotic mixture, for a period of 3 weeks, during which cell 
viability and proliferation was studied using Alamar Blue assay. 
 
Effect of Scaffold Geometry: Rolling up the flat rectangular scaffolds into cylindrical 
constructs could simulate the cylindrical shape of tendon and ligaments (Figure 4.17). 
 
               
Figure 4.17: Rolling of flat scaffolds to create cylindrical constructs (image courtesy of 
Teh Kok-Hiong Thomas, Tissue Repair Lab, National University of Singapore) 
 
 
 To study how rolling up of scaffolds affected their mechanical properties, a pilot 
study was conducted using knitted scaffolds of the same dimensions (20mm × 40mm), 
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fabricated out of an alternative biomaterial (poly-L-lactic acid, PLLA) also used for 
tendon and ligament tissue engineering. Three scaffolds of each group (flat or rolled 
geometry) were tested to failure and their mechanical properties were compared. 
 
 Cell proliferation in both geometries of the silk-PLGA hybrid scaffolds were also 
studied and compared. 4 hybrid scaffolds were seeded with 2 million rabbit BMSCs on 
one surface, and another 4 were seeded with 1 million cells on one surface and 1 
million cells on the other surface on the subsequent day. On the 7th day of culture, 
when the cell-seeded constructs usually achieve a critical density or confluence of 
cells, they were rolled up using sterile forceps, and sutured near their ends using sterile 
degummed silk fibers. Culture was continued for another 2 weeks during which cell 
proliferation was measured using Alamar Blue assay, results of which were compared 
against those obtained from simultaneously cultured flat scaffolds (as described in the 
preceding section).  
 
 Since Alamar Blue assay relies on dye diffusion into/from the cells, across the 
scaffold, it is likely that diffusion constraints in a 3-dimensional rolled-up scaffold 
would result in an under-estimation of cell proliferation, as compared to flat 
rectangular scaffolds. A more accurate representation could be obtained by DNA-
quantitation using PicoGreen assay (Appendix B.3.3).  Thus, after performing 
Alamar Blue assay on the “1M2” flat and rolled-up scaffolds on day 21, the scaffolds 
were freeze-dried, thawed, minced and then homogenized in 1 ml of a lysis buffer. The 
lysis buffer was prepared by mixing 900 µl TE buffer from the PicoGreen kit 
(Molecular Probes, Invitrogen Corporation) with 100 µl of RLT Buffer (Qiagen 
easyRNA extraction kit), supplemented with 1:100 β-mercaptoethanol. The lysates 
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were centrifuged and 20µL of the supernatants were added to 80µl of PicoGreen dye 
(diluted in 1× TE Buffer) in separate wells of a black 96-well plate (NUNC). 
Fluorescence intensity (expressed in relative fluorescence units, RFU) at 520 nm 
wavelength was measured using a microplate reader (FLUOstar OPTIMA, BMG 
Labtech GmbH, Germany) after excitation at 485 nm, using a gain of 1000, 10 flashes 
per well, and a position delay time of 0.2-0.5 second. 
 
4.4.2 Results and Discussion 
 
Fabrication of Hybrid Scaffolds: The hybrid scaffolds, fabricated by coating 
nanofibers onto silk solution-wetted silk scaffolds placed on the rotating frames, 
showed better adhesion of the nanofibre layers to the knitted scaffold. The scaffolds 
allowed easier handling, without risk of separation of the layers. 
 
Study of the Effect of the Silk Solution on Knitted Silk Scaffolds:  
(i) The dried silk films were observed to be insoluble in water, and retained their 
morphology for the duration of study. 
(ii) SEM images of the silk scaffolds, coated with silk solution and dried, showed a 
layer of silk film on the knitted fibers (Figure 4.18A). SEM image of this scaffold after 
coating with nanofibers showed nanofibers being glued on to the knitted fibers (Figure 
4.18B). The total protein concentration in the medium in which the silk scaffolds were 
soaked was lower (30.2 µg/ml) than in the fresh medium (33.3 µg/ml). This suggested 
that silk proteins were not being eluted from the scaffolds into the culture medium; 
(iii) Mechanical tests results (Table 4.2, Figure 4.19) showed that the silk film did not 
significantly affect the mechanical properties of the hybrid scaffolds. Coating with the 
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silk film caused only a slight decrease of the failure load and a small increase in 
stiffness of the knitted silk scaffolds; while the failure load dropped over the 3 days of 
soaking in culture medium, the stiffness values increased. However, owing to 




Figure 4.18: SEM images of a silk scaffold, after coating with silk solution (A) and 
after further coating with nanofibers (B) 
 




















































 The ultimate tensile strength (UTS) of coated scaffolds was estimated to be 
significantly lower than that of uncoated scaffolds (p<0.05). This fall is likely due to 
an increase in the estimated cross-sectional area of the scaffolds. With the dried silk 
solution, the scaffolds were stiffer and resisted rolling up, and thus their diameters 
were generally larger (2.49mm) than that of uncoated scaffolds (1.94mm). However, 
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Figure 4.19: Mechanical test results showing similar mechanical properties of coated 




Cell Seeding Protocol Optimization: During the 3 weeks of culture, cell proliferation 
was higher on the scaffolds seeded on both surfaces (1M2) compared to those seeded 
only one surface (2M1). At the end of the 3rd week, 1M2 group had 14.2% higher cell 
proliferation that the 2M1 group (Figure 4.20). This was likely due to the availability 
of a larger surface area for cell proliferation in scaffolds of 1M2 group. 
 
 
Figure 4.20: Cell viability was consistently higher on scaffolds seeded on both surfaces 




Effect of Scaffold Geometry: Rolling up the scaffolds resulted in a 15% increase in 
the failure load (48.7 ± 1.86 N from 42.2 ± 2.42 N; p<0.05) and a 12% increase in 
stiffness (8.8 ± 1.08 N/mm from 7.9 ± 0.99 N; p>0.05). The failure pattern of the 
cylindrical scaffolds was also different, failing closer to the center (C-D), as against 








Cell proliferation was observed to be lower in rolled-up scaffolds than in flat 
scaffolds (14.5% lower in 2M1 and 12.4% lower in 1M2, at end of 3rd week; Figure 
4.22). The lower rate could be due to one or more factors: diffusion limitations of the 
Alamar Blue method, cell death/damage during the process of rolling up of the 
scaffolds, or nutrients transmission problems at the interior of the rolled-up scaffolds. 
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Figure 4.22: Alamar Blue Assays showing lower cell proliferation in rolled-up 
scaffolds than in flat scaffolds, with either type of cell seeding 
  
  
 The PicoGreen assay confirmed that rolled-up scaffolds had a lower number of 
cells; Pico Green values were only 6% lower, as compared with Alamar Blue values 
that were 12.4% lower in rolled-up scaffolds compared to flat scaffolds at the end of 
3rd week (Table 4.3). The results also confirmed that the cell proliferation in rolled-up 
scaffolds was indeed under-estimated by Alamar Blue. 
 
Table 4.3: Comparison of PicoGreen and Alamar Blue assay results for cell 
proliferation on rolled-up and flat scaffolds at the end of 3 weeks 
 
 Alamar Blue (% reduction) 
PicoGreen  
(RFU) 
Flat 79.88 ± 9.34 54.00 ± 15.56 
Rolled-up 70.00 ± 7.71 50.75 ± 8.84 
 
 
 However, in the rolled scaffolds, when cells were seeded on both surfaces (1M2), 
cell proliferation was about 17.0% higher at the end of 3 weeks, as compared to 







Figure 4.23: 17% higher cell proliferation in the rolled scaffolds, at the end of 3 weeks, 







(i) Knitted scaffolds fabricated from 3 yarns of silk fibers, when degummed by 
boiling in 0.25% Na2CO3 solution with addition of a detergent (1% SDS) and 
intermittent ultrasonic agitation, showed improved sericin removal and better 
mechanical properties. Such degummed scaffolds satisfied the requirements of 
the study, which was to obtain a scaffold of 20 mm × 40mm dimensions that 
could withstand a failure load of 60-100N.  
(ii) After coating with nanofibers, using a 2% silk solution as glue and a rotating 
frame as a collector, biocompatible and mechanically robust hybrid nano-
microscaffolds could be created. The silk coating was shown to be stable; other 
studies have also reported similar stability of silk films (205, 206). 
(iii) Seeding these hybrid scaffolds on both surfaces yielded better cell proliferation 
than seeding on only one surface. Rolling up the cell-seeded hybrid scaffolds 
after 7 days of culture could yield cylindrical analogues that resembled the 
shape of a tendon graft.  
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A study using braided scaffolds had shown that scaffolds with a circular 
cross-section possessed better mechanical properties as compared to those with 
a rectangular cross-section (24). Similarly, rolling-up the rectangular knitted 
scaffolds into cylindrical structures also resulted in an increase of the failure 
load and stiffness of the knitted scaffolds. 
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5 Chapter 5 
 





Use of mesenchymal stem cells, derived from replenishable sources like the bone 
marrow, has an advantage over use of differentiated cells that would require harvesting 
and enzymatic digestion of healthy tissues from donor sites. However, such stem cells 
would need to be induced to proliferate and then differentiate into the desired 
phenotype by providing them with adequate chemical, mechanical or biological 
stimuli. In Stage I of this study, it was shown that BMSC seeded on the novel PLGA 
nano-microscaffolds could differentiate into tendon lineage, even without any specific 
attempt to direct such differentiation.  
 
A common biological stimulus used to aid in proliferation and differentiation of 
various stem cells are protein growth factors. In most studies, growth factors are 
supplied directly into the culture medium; this is feasible only in vitro but not in in 
vivo applications, where instead of repetitive administration, it is desirable to have a 
sustained release of bioactive growth factor from the scaffold. Hydrogel-based 
delivery is most commonly employed, which however has limitations like cell death in 
the depths of the scaffolds as well as poor mechanical properties. The versatility of the 
electrospinning technique offers a possibility of incorporating protein growth factors 
within polymer nanofibres, which could then serve as a source of continued and 
 93 
 
controlled release of the growth factor (53-56, 166). As mentioned in Section 2.1.4, 
bFGF is known to stimulate mesenchymal stem cell proliferation, self-renewal and 
differentiation into fibroblastic lineages (163). Incorporating the growth factor into 
nanofibres would ensure continued local release of the growth factor, allowing 
proliferation and differentiation of the seeded BMSCs. As the tissue levels of bFGF 
and its receptors are known to be increased mostly in the 1st week of injury (61, 88-
91), a bFGF release profile sustained over 1 week is hypothesised to be suitable for 
inducing optimal proliferation and differentiation of BMSCs into tendon fibroblasts.  
 
In this stage of the study, two modifications of the electrospinning technique were 
developed to fabricate bFGF-releasing PLGA nanofibres, using 
blending/emulsification and electrospinning (Group I) or coaxial electrospinning 
(Group II). The nanofibre matrices were characterized morphologically, physico-
chemically and also biologically to evaluate their efficacy for allowing 
tendon/ligament regeneration from stem cells. Based on this comparative study, one of 
the groups would be chosen for further studies to characterize BMSC differentiation on 
the scaffolds. Such nanofibres when coated over a knitted silk scaffold can produce a 
biohybrid nano-microscaffold that is not only mechanically strong but also has 




5.2 Comparison of Blend and Coaxial Electrospun Nanofibres as 
Growth Factor Delivering Scaffolds  
 
 





Scaffold Fabrication: During the optimization phases of scaffold fabrication, 
the original composition of PLGA, as that used in Stage I of the research, 25% 
PLA65:PGA35 (Birmingham Polymers, Birmingham, AL) in a 1:1 mixture of THF 
and DMF, was used. Since this solvent system was immiscible with water, 2.5μL of 
Tween20 (Sigma Aldrich, USA) was used as a surfactant and 10μL of 10% BSA was 
used as a stabilizer in a 10μg/100μL of bFGF, and mixed by vortexing for 2 minutes. 
The resulting solution was added slowly to 2ml of 25% PLGA solution, vortexed and 
then sonicated for 1 minute at room temperature to create a water-in-oil emulsion. For 
control studies, the FGF-2 solution was replaced by 100μL of reconstituting medium, 
keeping all other materials and conditions constant. 
 
However, these protein-polymer scaffolds lacked dimensional stability and 
contracted significantly on soaking in PBS at 37ºC, and subsequently detached from 
the cover-slips (Figure 5.1). Such phenomenon has been previously reported in PLGA 
nanofibrous scaffolds (28) and was also encountered after substituting the PLGA with 




Figure 5.1: Shrinkage of PLGA (PLA65:PGA35) nanofibrous scaffolds after 





This contraction was likely caused by the fact that PLGA nanofibres contain 
highly oriented and extended amorphous chains that relax when the nanofibrous fats 
are incubated at 37ºC, which is close to the glass transition temperatures (Tg) of 
nanofibrous PLGA (28). A PLGA formulation with a different PLA:PGA ratio 
(PLA85:PGA15; Purac Asia Pacific, Singapore) was next used to fabricate the 
nanofibers and such nanofibers possessed excellent dimensional stability and did not 
show any shrinkage. All future experiments used this formulation of PLGA. 
 
Group I nanofibres were fabricated by mixing an aqueous solution of 20μg of 
lyophilized bFGF (Raybiotech USA) in 333µL of 5mM TRIS (pH 7.6) containing 
0.1% Bovine Serum Albumin (BSA; Sigma Aldrich, St. Louis, USA), with 1.5ml of 
6.1% PLGA (PLA85:PGA15; Purac Asia Pacific, Singapore) solution in HFIP (Fluka 
Chemie GmBH, Germany). After vortexing for 1 minute, this blend was electrospun 
using a high voltage power supply unit (RR 30-2P/DDPM, Gamma High-Voltage 
Research, Ormond, USA), at 10-12kV and a flow-rate of 0.45 ml/hour, onto several 
round glass cover-slips placed on a grounded collector, about 15 cm from the 
positively-charged spinneret. 
 
Group II nanofibres were fabricated by using a coaxial electrospinning set-up 
(Figure 2.4). Using the same solutions but instead of mixing them as in Group I, the 
bFGF solution was kept in the inner channel of the set-up and the PLGA solution in 
the outer channel. Electrospinning was performed at a similar voltage, using a flow-
rate of 0.1 ml/hour for the inner solution and 0.35 ml/hour for the outer solution. The 




Table 5.1: Protein and PLGA composition in the blend for electrospinning 
 




0.020  mg 
BSA 0.1% 0.333  mg 
PLGA 6.1% 1500 μL 91.50  mg 
Total   91.853 mg 
 
 
Control scaffolds not containing bFGF were also fabricated for both groups by 
replacing the bFGF solution with 5mM TRIS buffer (pH 7.6) containing 0.1% BSA. 
The bFGF containing scaffolds are termed (+) and those without are termed as (-) in 
each group. The scaffolds were vacuum-dried at room temperature overnight and then 
kept in a desiccator at 4°C until further use. 
 
Scaffold Characterization. The scaffolds were characterized for their morphology, 
protein distribution and hydrophilicity, using a variety of techniques: 
 
(i) Light Microscopy. The nanofibre matrices collected on glass slides were 
characterized morphologically by light microscopy (IX71 Inverted Research 
Microscope, Olympus) and analyzed by image analysis software (Olympus 
MicroImage v4.5.1, Olympus Optical Co., Germany). 
 
(ii) Scanning Electron Microscopy. The nanoscaffolds were sputter-coated with gold 
and their morphology observed by SEM (JSM-5800LV, JEOL, Tokyo, Japan) at 
100kV accelerating voltage. 
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(iii)  Atomic Force Microscopy. Nanofibers were collected on mica films, and imaged 
using an AFM (Quartz, Cavendish Instruments Ltd., UK); the images were processed 
and analyzed using MultiView 1000 software (Nanonics Imaging Ltd., Israel). 
 
(iv) Fluorescence Microscopy. FITC-conjugated BSA (Sigma Aldrich, St. Louis, 
USA) was used as a model protein to study protein distribution within the nanofibres 
by fluorescence microscopy using a laser scanning confocal microscope (LSCM, Leica 
TCS SP2, Germany).  
 
(v) Static Water Surface Contact Angle. Surface contact angle (SCA; VCA-Optima, 
AST Products Inc., MA, USA) measurements were performed on the various 
scaffolds, and also on pure PLGA nanofibrous scaffolds. Since the rough surface of 
nanofibrous scaffolds could potentially confound SCA measurements, overestimating 
the hydrophobicity of surfaces, thin films of PLGA and PLGA-BSA blends were also 
used as additional controls. 
 
(vi) Fourier Transform Infrared (FTIR) Spectroscopy. FTIR Spectroscopy was 
performed on the coaxial and blend scaffolds to ascertain the presence of proteins in 
the nanofibres. 
 
(vii) Transmission Electron Microscopy. Transmission Electron Microscopy (TEM, 
JEOL JEM-2010F) was also performed to further confirm the results after collecting 
the nanofibres on formvar-coated copper grids, carbon-coating and drying in a vacuum 




Protein Release Kinetics. Nanofibrous scaffolds were collected on 35mm diameter 
glass cover-slips, that were weighed before and after electrospinning the nanofibres on 
them, to estimate the average weight of the nanofibre matrix on each cover-slip. The 
cover-slips (n=24) with nanofibre-matrix were placed in separate wells of a 6-well 
plate, were incubated in a release buffer comprising 1× PBS with 0.1% BSA and 
0.01% sodium azide (Fluka Chemie GmBH, Germany), at 37°C over a period of 2 
weeks. The release-medium was collected at specified intervals (days 1, 3, 7, 10, 14) 
and the kinetics of bFGF release from the scaffolds (n=3) were analyzed by ELISA 
using a FGF-2 ELISA kit (Calbiochem, Merck KGaA, Germany) with sensitivity of 3 
pg/ml of FGF-2. 
 
Efficiency of loading or encapsulation of protein in the nanofibers for the two 
electrospinning methods was determined by base-surfactant method (cite). Scaffolds of 
each group (n=3) were dried, weighed and subjected to hydrolysis in 0.1 N NaOH, 5M 
Urea, 0.08% SDS in 50mM Tris extraction medium at 37 ˚C for 3 hours. After 
neutralization with 0.1 N HCL and centrifugation, the protein concentration in the 
supernatant was measured. As bFGF levels after such base-surfactant extraction were 
below the detection levels of the ELISA kit, total protein content in the supernatant 
were measured by Bradford microassay. Protein encapsulation efficiency was 
calculated from the ratio of the protein content in the supernatant to the theoretically 
obtained total protein content of the electrospun scaffolds. 
 
 
BMSC Seeding and Culture on Scaffolds: Rabbit BMSCs were isolated and cultured 
by as described previously in Chapter 4. Semi-confluent cells of second or third 
passage were used for cell seeding experiments. Nanofibrous scaffolds, collected on 32 
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mm diameter glass cover-slips, were sterilized by exposure to formaldehyde gas for 1 
hour followed by degassing overnight in the biosafety cabinet. Scaffolds were placed 
in 6-well plates and seeded with rabbit BMSCs at a density of 104cells/cm2 in DMEM-
High Glucose (Sigma Aldrich, USA) supplemented with 5% FBS and 1% Penicillin-
Streptomycin (GIBCO) (Figure 5.2A).  
 
An optimization study of BMSC culture using growth media supplemented with 
various concentrations of FBS and bFGF, with an aim to establish serum-free or 
serum-poor culture conditions for BMSC (Appendix B.7), had shown that media 
containing 10% FBS confounded the effect of bFGF released from the scaffolds. This 
is likely as FBS is a rich source of a multitude of growth factors including bFGF which 
is present at a concentration of 292 ± 320 pg/mL (207). This study also showed that 
5% FBS was the minimum concentration of supplementation that allowed rabbit 
BMSCs to proliferate well, while at the same time, allowed detection of effects on 
low-dose bFGF supplementation. 
 
The BMSC-seeded constructs were cultured in a 5% CO2 incubator at 37˚ C for 2 
weeks, with the medium being replaced every 3 days.  
 
Cell Seeding Efficiency: The cell seeding efficiency was estimated from the 
proportion of unattached cells in the culture medium, 18 hours post-seeding, following 
the method described previously in Stage I. After incubating the cell-seeded scaffolds 
(n=6, for each scaffold type) for 18 hours, the culture medium was collected from the 
wells into separate centrifuge tubes. The cell pellets obtained after centrifugation were 
re-suspended in 100µL of medium and cell count performed. The cell seeding 
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efficiency is expressed as the number of cells attached to the scaffold as percentage of 
the number of cells seeded. 
 
Live Cell Staining and SEM Imaging of Cell Proliferation: FDA was used to stain 
the live cells on the construct (details in Appendix B.4). After removing the culture 
medium, cell-seeded scaffolds were rinsed with 1×PBS and then incubated in 1ml 
1×PBS supplemented with 2µl FDA (5 mg/ml) for 30 minutes at 37ºC. After rinsing 
twice with 1×PBS, the green-stained live cells were visualized using an inverted 
fluorescence microscope (IX71 Inverted Research Microscope, Olympus) under blue 
excitation. 
 
For SEM, the samples were rinsed with 1×PBS, fixed with 3.7% formaldehyde for 
30 min and then rinsed with tap water. The samples were then dehydrated in graded 
concentrations of ethanol and then air dried overnight. The dried samples were sputter-
coated with gold at 10mA, 10 psi, 50-60s (JFC-1200 Fine Coater, JEOL) and observed 
under the SEM (JSM-5800LV, JEOL) at an accelerating voltage of 15 kV. 
 
Cell Proliferation Assay: Cell proliferation on the scaffolds was estimated by DNA 
quantitation using the PicoGreen assay (Molecular Probes, Invitrogen Corporation) on 
the 3rd, 7th and 14th day of in vitro culture. After a cycle of freeze-thawing and freeze-
drying, 400 µl of lysis buffer was added to each well and mixed well by pipetting. The 
lysis buffer was prepared by mixing 9 parts of TE buffer from the PicoGreen kit 
(Molecular Probes, Invitrogen Corporation) and 1 part of RLT Buffer (Qiagen 




The cell-lysate was carefully aspirated into a 1.5 ml microcentrifuge tube, 
vortexed for 6 minutes and centrifuged at 13,000 rpm for 10 minutes. 20µl of the 
supernatant was added to separate wells in a 96 NUNC black well plate containing 
80µl of pre-warmed PicoGreen dye, and mixed by pipetting. Fluorescence intensity at 
520 nm wavelength was measured using a microplate reader (FLUOstar OPTIMA, 
BMG Labtech GmbH, Germany) after excitation at 485 nm, using a gain of 1000, 10 
flashes per well, and a position delay time of 0.2-0.5s. BMSC proliferation on TCP in 
DMEM-HG with 5% FBS was also measured as a control. 
 
 
Collagen production (Sircol Assay):  Collagen being one of the key 
components of the tendon/ligament ECM, it is vital that it is produced in abundant 
amounts by the seeded cells. Moreover, increased collagen production and deposition 
would also be indicative of stem cell differentiation into a fibroblastic lineage.  
 
On the 3rd, 7th and 14th day of culture, the total soluble collagen synthesized and 
secreted into the culture medium was determined by SirCol® Assay (Biocolor Ltd, 
Northern Ireland) using previously described methods (177). The culture medium was 
replaced by fresh DMEM with 5% FBS, 2 days prior to the day of assay, to ensure that 
only freshly synthesized soluble collagen was assayed. Absorbance of PicroSirius Red 
stained collagen was read at 540nm (TECAN Microplate Reader, Magellan Instrument 
Control and Data Analysis Software) to obtain the concentration of collagen in the 
medium, which was then multiplied with the total volume of medium collected from 
the respective scaffolds to give an estimate of the total amount of collagen secreted per 
scaffold over 2 days. Collagen production from BMSCs grown on TCP in DMEM-HG 
with 5% FBS was also measured as a control. 
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Q-RT-PCR Analysis for expression of fibrous ECM proteins from BMSCs: In 
addition to increased proliferation, bFGF is expected to induce fibroblastic 
differentiation of BMSC and an associated upregulation of gene expression for fibrous 
ECM proteins. The gene expression of two predominant fibrous ECM proteins, 
collagen type I and fibronectin, were studied and compared on the two scaffold groups.  
 
Total RNA was extracted from day 14 samples of the both scaffold groups (I(+) 
and II(+)) and also from BMSCs cultured on TCP under the same culture conditions 
(DMEM-HG with 5%FBS) using Qiagen RNeasy Kit®. The RNA extract was assessed 
for its purity and concentration of RNA by spectrophotometry and stored at -80°C. 
Quantitative or real time RT-PCR (Q-RT-PCR) was performed using SYBR-Green 
chemistry for collagen type I and fibronectin, using GAPDH and β-actin as reference 
genes. The primer sequences (as in Table 5.2) were either obtained from published 
literature or designed from rabbit gene sequences obtained from the GenBank 
database, using Primer-3 software, and synthesized by Research Biolabs, Singapore 
and optimized for PCR efficiency and specificity.  
 
 Q-RT-PCR was performed using a 2-step method wherein cDNA was 
synthesized from RNA (iScript, Bio-Rad Laboratories, CA) followed by real time PCR 
expansion (iQ SYBR Green Supermix, Bio-Rad Laboratories, CA) using the specific 
primers on a iCycler iQ detection system (Bio-Rad Laboratories, CA). Data were 
analyzed for relative expression using the ∆∆ CT method, after normalization against 





Table 5.2: Real time PCR primers used in the study. Primers for collagen type I, 
GAPDH and β-actin were designed from NZWR gene sequences obtained from 
GenBank (accession numbers D49399, NM_001082253 and AF309819 respectively) 
using Primer3 software (http://frodo.wi.mit.edu). Other primers were obtained from 
published literature (208, 209) 
 
Primer Sequence 
Collagen I (α2) F: GCA TGT CTG GTT AGG AGA AAC C R: ATG TAT GCA ATG CTG TTC TTG C 
Collagen III (α1) F: AAG CCC CAG CAG AAA ATT G R: TGG TGG AAC AGC AAA AAT CA 
Fibronectin F: CTC ACC CGA GGC GCC ACC TA R: TCG CTC CCA CTC CTC TCC AAC G 
Biglycan F: TGA ACA ACA AGA TCT CCA AGA T R: ATT CAG GGT CTC TGG CAG A 
GADPH F: GAC ATC AAG AAG GTG GTG AAG C R: CTT CAC AAA GTG GTC ATT GAG G 
β-Actin F: CCC ATC TAC GAG GGC TAC G R: CCA CGT AGC ACA GCT TCT CC 
 
 
Data reduction and Statistical analysis:  Data were presented as mean ± standard 
deviation. Multiple comparision were performed by single-factor ANOVA and.post-
hoc Bonferroni tests. For pair-wise comparisons, two-tailed, unpaired Student’s t-tests 






Scaffold Characterization: Scaffolds of both Group I (blend) and II (coaxial) were 
observed to be composed of continuous nanofibres of 200-700nm diameter, by optical 
(Figure 5.2B) and SEM (Figure 5.3D) observation. AFM images (Figure 5.3A-C) 
showed that after prolonged electrospinning, the nanofibres were grouped into parallel 
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       A                                                           B 
Figure 5.2: A. BMSCs cultured on nanofiber scaffolds; B. Phase contrast image 





Figure 5.3: 2-D (A) and 3-D (C) AFM images showing Group I nanofibres of 500-700 
nm diameter, as measured by profiling along x-y (B); SEM image (D) showing thinner 




FTIR studies indicated that protein was incorporated in both groups of nanofibres; 
the presence of additional peaks at 1635 and 1644cm-1, corresponding to protein 
Amide I and at 1534 cm-1, corresponding to protein Amide II is characteristic of 
proteins (Figure 5.4). The peaks were more prominent on the Group I (blend) fibers, 
presumably due to a more superficial arrangement of the proteins on these fibers. All 
nanofibers had a characteristic peak at 1758 cm-1 corresponding to C=O stretch in the 
PLGA molecule (210).  
 
Figure 5.4: FTIR spectra demonstrating presence of proteins in the Group I (in red) 
and Group II nanofibres (in green) indicated by characteristic protein Amide-I  peaks 
(1635/1644 cm-1) and protein Amide II peak (1534 cm-1) that are absent in the 
spectral plot of pure PLGA nanofibers (in blue) 
 
 
Group I (blend) scaffolds were less hydrophobic (SCA, 121.1°) than Group II 
(coaxial; SCA, 128.4°) and PLGA-only nanoscaffolds (SCA, 129.1°). As with rough 
nanofibrous scaffolds, thin films made of the PLGA-protein blend used to fabricate the 
Group I scaffolds were also less hydrophobic (SCA, 80°) compared to PLGA films 
(SCA, 94.5°) suggesting that blending resulted in random dispersion and a  more 
superficial distribution of proteins in the nanofibres (Figure 5.5). This was confirmed 
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by LSCM and TEM (Figure 5.6), which showed a random dispersion of proteins 
within Group I nanofibres but a “core-shell” structure within Group II nanofibres. 
 
Figure 5.5: Surface contact angles of the different nanofibres, and of PLGA and blend 







Figure 5.6: LSCM and TEM images showing different protein distribution patterns in 




Protein Release Kinetics: Both scaffold groups had a similar protein encapsulation 
efficiency of 54± 5%. Release kinetics results indicate that both scaffolds could sustain 
a release for 1 week. Compared to Group I scaffolds, which released all the 
encapsulated bFGF in 7 days, Group II scaffolds could sustain the release till 14 days. 
The cumulative release profile from the two scaffold groups are plotted in Figure 5.7. 
 
Figure 5.7: bFGF release profile showing similar release pattern, prolonged over 
atleast 1 week, from both nanofiber groups 
 
 
Cell Seeding Efficiency and Cell Proliferation (Live Cell Staining, SEM, 
PicoGreen Assay): More than 90% of the seeded rabbit BMSCs attached onto the 
scaffolds in 18 hours. Better cell proliferation and spreading was observed on bFGF 
releasing scaffolds, especially in Group I, by fluorescent microscopy after live cell 
staining with FDA and SEM (Figure 5.8).  
 
PicoGreen assay corroborated the above findings showing that the cell population 
on the Group I (+ and -) scaffolds increased gradually and consistently over the 2 
weeks of culture. Scaffolds containing bFGF always showed higher cell proliferation 
compared to the respective control scaffolds without bFGF. On day 14, Group I (+) 
scaffolds had significantly higher cell population as compared with Group I (-) 
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scaffolds on the same day; similarly, Group II (+) scaffolds had higher cell 
proliferation compared to Group II (-). No statistical difference was observed between 
Group I and Group II scaffolds. Cells cultured on TCP gave prominently higher 
readings compared to the various scaffolds (Figure 5.8). 
 
 
Figure 5.8: BMSC proliferation on various scaffolds over 2 weeks; better cell 
proliferation on bFGF-delivering Group I and II scaffolds, compared to scaffolds 
without bFGF, as demonstrated by PicoGreen assay, fluorescence microscopy after 




Collagen production: Sircol Assay: No definite trend could be observed from the 
Sircol assays and collagen production was similar on the various scaffolds and TCP 
substrate during the 2 weeks of culture (Figure 5.9). In all the sets, the values dropped 
from day 3 to day 7 but showed an increase at day 14. Day 3 values could be falsely 
high due to proteins from unattached dead cells, derived from the seeded cell 
population, in the assayed culture medium. On the bFGF(+) scaffolds, there was no 
significant increase in collagen production from day 7 to day 14; in comparison, 
collagen secretion from bFGF(-) scaffolds increased significantly over this period to 




Figure 5.9: Soluble collagen production from the scaffolds over 2 weeks of culture: an 




Since the total cell number on the different scaffolds were different on the various 
time points, collagen production was normalized against the respective cell 
proliferation assay values, and against the TCP value on day 3, to determine the 
average collagen production per cell (Figure 5.10). Group I scaffolds produced showed 
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significantly higher average collagen production on day 3, as compared to Group II 
scaffolds and TCP. By day 7, bFGF-releasing scaffolds showed significantly higher 
average collagen production (Group I (+): 53% higher, Group II (+): 47% higher) than 
the respective controls. All nanofibrous scaffolds had higher collagen production 




Figure 5.10: Normalized values of collagen production: cell proliferation on the 
scaffolds over 2 weeks of culture; bFGF-releasing scaffolds showed significantly 
higher average collagen production (Group I (+): 53% higher, Group II (+): 47% 
higher) than the respective controls. 
 
 
Q-RT-PCR analysis for expression of fibrous ECM proteins from BMSCs: Q-RT-
PCR results showed that the fibrous ECM proteins, collagen type I and fibrinogen, 
were over-expressed in cells grown on the bFGF-releasing Group I (blend) 
nanofibrous scaffolds (34% and 240% higher than expression on TCP control) in 
comparison to cells grown on Group II (coaxial) scaffolds (76% and 48% lower than 




Figure 5.11: Q-RT-PCR analysis showing a significant gene upregulation of fibrous 
ECM proteins (Col 1: Collagen type I, Fbn: Fibronectin) on Group I (+) scaffolds after 





It was found that: 
(i) both Group I and Group II scaffolds were composed of smooth continuous 
nanofibers, with proteins successfully incorporated in them, randomly 
dispersed in Group I and as a central core within Group II nanofibres; 
(ii) both scaffold groups allowed continued release of bioactive growth factor over 
a period of 1 week. Group II (coaxial) scaffolds allowed a slightly longer 
sustained release of the encapsulated growth factor; 
(iii) While Group I (blend) scaffolds were more hydrophilic, both groups favoured 
BMSC attachment and cell proliferation was better on the bFGF-releasing 
scaffolds compared to respective controls without the growth factor; 
(iv) Though total soluble collagen production was similar on the different scaffolds, 
the average collagen production per cell was higher on the bFGF-releasing 
scaffolds than their respective controls on day 7. 
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(v) On day 14, gene expression for collagen type I and  fibronectin were better on 
bFGF-releasing Group I scaffolds compared to their Group II counterparts. 
 
While the encapsulation efficiency and release profile were similar for blend and 
coaxial nanofibers, the technique of blend-electrospinning was relatively more facile 
than coaxial-electrospinning. Group I scaffolds therefore have the advantage over 
Group II scaffolds, and were chosen for a more detailed study to characterize BMSC 
differentiation on the scaffolds for tendon/ligament tissue engineering application. 
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5.3   Additional Characterization of bFGF-Delivering Blend 





5.3.1 Materials and Methods 
 
Demonstration of bioactivity of released bFGF (Western blot for phosphorylated 
tyrosine kinases in BMSCs): While detection of bFGF by ELISA and stimulation of 
BMSC proliferation and differentiation on FGF-2 releasing scaffolds indicate that 
incorporated FGF-2 was released in a bioactive form, a direct demonstration, using a 
molecular biology approach, that the released bFGF could affect the seeded BMSCs 
would be very useful. bFGF acts through cell surface receptors that activate several 
intracellular second messengers (ERK/ MAPK cascade) by phosphorylation of their 








Tyrosine phosphorylation events involved in the bFGF-mediated signal 
transduction pathways were studied in the BMSCs seeded on the group I nanofibrous 
scaffolds, with or without bFGF, fabricated as described earlier. BMSCs were grown 
on the 2 sets of scaffolds, in DMEM-HG with 5% FBS for 1 week. On the 7th day, the 
culture medium was removed, and the cells were rinsed in distilled water and stored at 
-80°C. 
 
Upon thawing, cells were lysed in a NP-40 lysis buffer (20mM Tris HCl at pH 8, 
100mM NaCl, 10% Glycerol, 1% nonidet P-40, 5mM Na2-EDTA) supplemented with 
several protease inhibitors (10mM sodium fluoride, 1mM sodium orthovanadate, 0.01× 
protease inhibitor cocktail (Sigma Aldrich, USA)) to inactivate various intracellular 
proteases, especially tyrosine and tryptophan proteases. After estimating the protein 
concentration in the lysates using Bradford method (Standard microplate assay, Bio-
Rad Protein Kit), 100µg of total cell lysates were separated on a 7.5% SDS-PAGE. 
 
After semi-dry electrotransfer onto a nitrocellulose membrane, blocking was 
performed with Tris-buffered saline (TBS) containing 1% BSA, and the membrane 
then incubated with phosphotyrosine antibody (pY20, mouse IgG, BD Biosciences, 
USA). A non-milk blocking solution was used as milk proteins can interfere with 
binding of the pY20 antibody. GAPDH was probed with anti-GAPDH as a loading 
control on a duplicate membrane. Detection was performed using horse radish 
peroxidase-conjugated secondary antibody (anti-mouse IgG) and TMB Substrate 
(Sigma ProteoQwest™ Colorimetric Western Blotting Kit). The blot was visualized 
using a gel documentation system (Syngene G:BOX,  Synoptics Ltd, Cambridge, UK) 
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and differences in phosphotyrosine levels in the two cell populations were measured 
using densitometric analysis (Quantity-One 4.4.0, BioRad). 
 
BMSC differentiation assays to demonstrate loss of multipotentiality of BMSCs 
cultured on bFGF releasing PLGA nanofibrous scaffolds: It is desirable that, 
besides increased proliferation, the bioactive growth factor from the nanofibrous 
scaffolds also directs differentiation of the seeded stem cells along a fibroblastic 
lineage. A lack of cell-surface markers for rabbit BMSC and tendon/ligament cells 
makes it impossible to confirm such differentiation (67). However, on lineage-specific 
differentiation, the committed progeny of the BMSC should demonstrate a loss or 
reduction in their multipotentiality, or ability to differentiate into bone, cartilage and 
adipose tissues. 
 
Primary rabbit BMSCs of P3 passage were induced to differentiate, in various 
induction media, into adipogenic, osteogenic and chondrogenic lineages, using 
previously described protocols (212, 213). Briefly, 3×105 cells were seeded per well in 
6-well plates for adipogenic and osteogenic differentiation, and 6×105 cells were 
grown in a pellet culture for chondrogenic differentiation. Adipogenic differentiation 
was induced by 3 cycles of induction (with DMEM supplemented with 10% FBS, 
0.5mM 1-methyl-3-isobutylxanthine, 1µM dexamethasone, 10µg/ml insulin, 0.2mM 
indomethacin and antibiotics) and maintenance treatment (with DMEM supplemented 
with 10% FBS, 10µg/ml insulin and antibiotics). Differentiation was then detected by 
Oil Red-O staining for lipid vacuoles. Chondrogenic differentiation was induced by 
culturing a BMSC-pellet in a serum-free DMEM with TGF-β1, 50µg/ml L-ascorbic 
acid 2-phosphate, 1.25mg/ml BSA, 0.1µM dexamethasone and 1× ITS (insulin-
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transferrin-selenium) and antibiotics supplements. After 3 weeks, the cell-pellet was 
sectioned and stained with Alcian Blue for cartilage matrix-specific sulfated 
glycosaminoglycans and acidic sulfated mucosubstances. Osteogenic differentiation of 
MSCs was induced under the influence of 10mM β-glycerophosphate, 0.1µM 
dexamethasone, 50µg/ml L-ascorbic acid 2-phosphate and 10µg/ml insulin and 
Alizarin Red staining was carried out to detect calcium accumulation after 3 weeks. 
All the induction reagents, except ITS (Gibco) and TGF--β1 (R&D Systems, MN, 
USA), were from Sigma. 
 
P2 BMSCs were cultured on Group I (+) scaffolds in DMEM-HG with 5% FBS 
for 2 weeks, harvested by trypsinization and gentle shaking, and then induced to 
differentiate along adipogenic, osteogenic and chondrogenic lineages, following the 
above- mentioned protocols. After the end of 3 weeks, various staining were 
performed to ascertain specific BMSC differentiation. Images were obtained by phase 
contrast microscopy (IX71 Inverted Research Microscope, Olympus, Germany). 
 
Immunostaining for deposited ECM: While Sircol assays showed that collagen was 
produced and secreted in similar amounts by the seeded cells on all groups of 
scaffolds, it is important that the synthesized collagen was deposited as new ECM 
surrounding the cells/scaffold. Immunostaining was performed to detect the deposition 
of collagen type I and type III, and also tenascin-C, an ECM molecule present 
relatively abundantly in tendons. After 10 days of culture, cell-seeded scaffolds were 
fixed in 2% paraformaldehyde and labeled with primary monoclonal antibodies (anti-
collagen type I, type III and tenascin-C; ICN Biochemicals, Aurora, OH) at a 1:200 
dilution and left overnight at room temperature. Subsequently, alkaline phosphatase 
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conjugated anti-mouse secondary antibodies were administered at a 1:100 dilution for 
1 hour, and colorometric detection performed using DAB as the substrate (IHC Select 
DAB Kit, Chemicon, Millipore Corporation, MA, USA). Images were obtained by 
phase contrast microscopy (IX71 Inverted Research Microscope, Olympus, Germany). 
 
Q-RT-PCR Analysis for expression of ligament/tendon-specific ECM proteins 
from BMSCs: In the 1st part of the study, only gene expression of collagen type I and 
fibronectin were compared on the bFGF-releasing scaffolds, after 14 days of culture. A 
more detailed gene expression analysis was undertaken after including additional 
controls (Group I and II scaffolds without bFGF), time-points (day 7 and 14) and 
genes (collagen type III and biglycan, in addition to collagen type I and fibronectin) 
for analysis.  
 
Total RNA was extracted from day 7 and day 14 samples of the both scaffolds 
group and also from BMSCs cultured on TCP under the same culture conditions 
(DMEM-HG with 5%FBS) as described earlier. Q-RT-PCR was performed using 
SYBR-Green chemistry for the ECM proteins using GAPDH and β-actin as reference 
genes using primers indicated in Table 5.2. 
  
After performing Q-RT-PCR using a 2-step method as described earlier, data were 
analyzed for relative expression using the ∆∆ CT method, employing the “Gene Study” 
module of the software (iQ5 Version 2, Bio-Rad Laboratories, CA) for comparing 
different runs, that had 2 inter-run calibrator samples (TCP on day 7 and 14). Data 
were expressed after normalization against the expression profile of cells grown on 
TCP on day 7. Since bFGF-releasing nanofibrous scaffolds are expected to cause both 
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cell proliferation and differentiation, a “tissue score” that takes into account gene 
expression levels in the cells as well as the total number of cells in a particular 
scaffold, would be more informative about cell fate than cell proliferation or 
differentiation indices alone. The “tissue score” was determined as the product of the 
average of the relative gene-expression values for collagen type I, collagen type III, 
fibronectin and biglycan, and the respective relative cell proliferation index obtained 
from the PicoGreen assay. All data were normalized with respect to values from TCP 





Demonstration of bioactivity of released bFGF (Western blot for phosphorylated 
tyrosine kinases in BMSCs): Several tyrosine-phosphorylated proteins could 
be observed in the Western Blots of both groups (Figure 5.13). Sustained tyrosine 
phosphorylation and long term activation of ERK1 and ERK2 (p44 and p42), as well 
as FRS2 (p89) were observed in the cells grown on the Group I (+) scaffolds, proving 
that the bFGF incorporated in the scaffolds was being released in a bioactive form over 
an extended period of time. Other bands corresponding to p145 (FGF receptor) and 
p52 (shc) were also observed, with a slightly increased intensity in the bFGF+ 
scaffold’s lane. 
 
BMSC differentiation assays to demonstrate loss of multipotentiality of BMSCs 
cultured on bFGF releasing PLGA nanofibrous scaffolds: BMSCs could be 
successfully differentiated into adipocytic, osteocytic and chondrocytic lineages after 3 
weeks of specific induction, as demonstrated by Oil Red-O, Alizarin Red and Alcian 
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Blue staining. However, BMSCs cultured for 2 weeks on bFGF-releasing 
nanoscaffolds failed to show any adipocytic differentiation. Osteocytic and 
chondrocytic differentiation was also markedly reduced, as indicated by a significant 
reduction in Alizarin Red stained calcium deposits and Alcian Blue stained 
glycosaminoglycans matrix (Figure 5.14). 
 
 
Figure 5.13: Western blot analysis and quantitativedensitometry showing increased 
tyrosine phosphorlyation events in BMSCs cultured for 7 days on Group I (+) 




Figure 5.14: Oil red O, alizarin red and alcian blue staining, showing adipocytic (A), 
osteocytic (B) and chondrocytic (C) differentiation of BMSCs. Data demonstrate a 
reduction of multilineage differentiation potential of BMSCs after culture on bFGF-




Immunostaining for deposited ECM: Immunostaining revealed a denser deposition 
of type I and III collagen in the extracellular matrix on Group I (+) scaffolds as 
compared to control Group I (-) scaffolds after 10 days of culture. In addition, a denser 
deposition of tenascin-C, another tendon/ligament specific ECM protein, was also 
demonstrated (Figure 5.15). 
 
 
Figure 5.15: Immunostaining for collagen type I (C-I), type III (C-III) and tenascin-C 
(TC) on BMSC-seeded Group I (+) (top row) and Group I (-) (bottom row) scaffolds 
on day 10 
 
 
Q-RT-PCR analysis for gene expression of ligament/tendon-specific ECM 
proteins: Real-time RT-PCR analyses demonstrated up-regulation of gene expression 
for various tendon ECM proteins on nanofibrous scaffolds compared to cells grown on 
TCP, on day 7. The upregulation was most prominent on the Group I (+) scaffolds 
throughout the two weeks of culture. Group I (-) scaffolds also showed a favourable 
upregulation, similar to that on Group II (+) scaffolds; it was however significantly 
lower than that on Group I (+) scaffolds, but better than on Group II (-) scaffolds 
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(Figure 5.16). The tissue score, taking into account the average gene expression of 
Collagen type I and III, fibronectin and biglycan, as well as the cell proliferation rate 
on the particular scaffold, also showed that the BMSC-seeded Group I (+) scaffolds 




Figure 5.16: Q-RT-PCR analysis showing a significant gene upregulation of 




Figure 5.17: Tissue scores based on Q-RT-PCR and PicoGreen results showing 






(i) The released bFGF was shown to be bioactive, causing increased activation of 
tyrosine phosphorylation events in the BMSCs seeded on the Group I (+) 
scaffolds. 
(ii) BMSCs cultured on such scaffolds not only proliferated better, but also had 
diminished multipotentiality after two weeks, suggesting differentiation along a 
particular lineage. 
(iii) Increased production and deposition of collagens as well as tenascin-C, and 
upregulation of gene expression for tendon/ligament specific ECM proteins 
like collagen type I and III, fibronectin and biglycan, by cells on the bFGF-
releasing Group I scaffolds, showed that BMSCs were undergoing a 






Two types of polymeric nanoscaffolds capable of continued release of a bioactive 
growth factor were developed.  Group I scaffolds were more hydrophilic and allowed a 
sustained release of the encapsulated growth factor over 1 week, in a bioactive form. 
The scaffolds favoured BMSC attachment and proliferation, production and deposition 
of collagen as well as tenascin-C, and upregulation of gene expression for 




5.4.1 Nanofibres as vehicles for controlled delivery of bioactive molecules 
 
Several researchers have recently explored the potential of electrospun 
nanofibrous scaffolds to incorporate proteins like growth factors within the nanofibres 
(53-56). The incorporated protein is hypothesised to be released though a combination 
of degradation of the nanofibres and diffusion across nanopores (Figure 5.18) on the 
nanofibre surface (136, 214, 215). 
 
In this study, it was shown that the incorporated bFGF was released gradually in a 
bioactive form. The two methods used to incorporate the growth factor in the 
nanofibres could also help in tailoring its release profile. As both the concentration and 
the duration of exposure of the cells to bFGF affect cell behavior (163, 216) and since 
a combination of growth and differentiation factors are likely to play a role (217, 218), 
varying the dose and duration of release, as well as using a combination of growth 




Figure 5.18: SEM images showing pores on the surface of blend and coaxial 





5.4.2 Nanofibres as biomimetic nanotopographic substrates for cells 
 
In this study, BMSCs demonstrated gene upregulation of tendon/ligament matrix 
proteins after culture on Group I scaffolds without any bFGF. Stage I of this study had 
also shown that a PLGA nanofibre-coated knitted scaffold presented a biomimetic 
surface for cells aiding in BMSC differentiation into a tendon/ligament lineage, 
without any growth or differentiation factor supplementation. Recently, aligned 
nanofibres have been demonstrated to cause better alignment and collagen production 
from seeded ligament fibroblasts (219). These indicate that nanotopographic cues from 
a nanofibrous scaffold are likely to play an important role in determining cell behavior 
and fate.   
 
bFGF has been shown to aid in in vitro stem cell renewal and maintenance of 
multilineage differentiation potential of BMSC in 2-dimensional cultures on tissue 
culture polystyrene (162). The observation in this study of the differentiation of the 
seeded BMSCs, after 2 weeks of culture on bFGF-releasing nanoscaffolds, further 
suggests that the nanofibrous environment plays a crucial role in determining cell 
behaviour and fate. However the reason behind the cells behaving very differently on 
the Group II nanofibers, where the bFGF release profile was only slightly slower and 
more prolonged, is not fully understood. It is likely that physical differences in the 
Group I nanofibers, such as the observed lower surface contact angle and higher 
hydrophilicity, factors known to govern initial protein and cell adhesion, or other 
material properties such as surface chemistry, surface energy or topography of the 
nanofibers, which have not been investigated in this study, might be positively 




5.4.3 Effect of bFGF release profile on BMSC proliferation 
 
Inclusion of bFGF in either scaffold group resulted in increased cell proliferation. 
However, the PicoGreen readings obtained from cells grown in culture flasks (TCP) 
were higher; this was likely the result of a higher efficiency of DNA extraction from 
the cells grown on TCP as compared to those grown on nanofibrous scaffolds. A drop 
in cell proliferation values was observed on both Group II (+) and (-) scaffolds on day 
7. This could be because of the fact that the growth factor release from the coaxial 
Group II (+) scaffolds was not sufficiently high to stimulate cell proliferation. On the 
contrary, the faster release of bFGF from the Group I (+) scaffolds could sustain 
consistent cell proliferation. 
 
5.4.4 Effect of bFGF release profile on BMSC differentiation 
 
A comparison of the gene expression profiles on both groups of scaffolds also 
reveals that on day 7, collagen type I expression was lower on the Group I (+) 
scaffolds than on the Group I (-) scaffolds. This might be explained by the fact that the 
seeded BMSCs were maintained an actively proliferating undifferentiated stem cell 
phenotype by the high levels of bFGF from the Group I (+) scaffolds, whereas on the 
Group I (-) scaffolds, they were not proliferating as well and producing more collagen. 
The scenario was reversed by day 14, when sustained bFGF levels resulted in BMSC 
differentiation predominating over their proliferation and a resultant significant 
increase in collagen type I expression. A decrease in collagen type III expression was 
observed on all scaffolds from day 7 to day 14. As with collagen type I, the expression 
of collagen type III, fibronectin and biglycan also showed a similar trend on the Group 
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I scaffolds, being lower in Group I (+) on day 7, but higher by day 14 as compared to 
Group I (-). 
 
On the Group I (+) scaffolds, while the expression of collagen type I and biglycan 
increased between day 7 and 14, that of collagen type III and fibronectin decreased. 
Fibronectin, in particular, is known to play an important role in regulating initial cell 
attachment and cell survival. The down-regulation of fibronectin transcript levels in 
this study is consistent with other studies where cells were observed to synthesize and 
accumulate fibronectin during proliferation and early differentiation; once the cells 
reached maturation and accumulated collagenous ECMs, they sharply reduced the 
production of fibronectin (69, 221). Fibronectin is also known to be a marker for active 
reparative connective tissue processes, where it organizes cell-to-matrix interactions, 
provides a temporary substratum for migration and proliferation of cells and provides a 
template for collagen deposition, which increases stiffness and tensile strength of 
healing tissues (69). 
 
These results are supportive of the earlier hypothesis that a sustained release of 
bFGF over 1 week might be better suitable that a more prolonged release. The Group I 
(+) scaffold “biomimicks” the ECM of injured tendons in both structure and function 
by providing a nanofibrous topography as well as a week-long supply of bioactive 
bFGF to the resident cells. Usual in vitro culture conditions using 5-15% FBS have 
bFGF levels of 15-45 pg/ml (207). Previous studies have shown that BMSCs grown in 
culture medium supplemented with 0.1-10 ng/mL of bFGF and replenished twice 
weekly resulted in increased proliferation, self-renewal and differentiation into 
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fibroblastic cells (162, 163). However, in this study, a sustained bFGF level in the 




Polymeric nanoscaffolds capable of continued release of bioactive growth factors, 
with different release profiles and surface hydrophilicity, were developed. It was 
shown that between Group I and Group II scaffolds, Group I (+) scaffolds released the 
incorporated bFGF in a bioactive form over 1 week, were more hydrophilic, favoured 
BMSC attachment and, particularly, proliferation and differentiation into a 
tendon/ligament fibroblastic lineage. These nanofibres are suitable candidates for 
coating on a mechanically strong degummed knitted silk scaffold, developed in Stage 
II of this study, to produce biohybrid scaffolds that would not only possess ideal 
mechanical properties but would also be capable of continued release of regulatory 
biomolecules, allowing proliferation and differentiation of seeded stem cells to 
facilitate tendon/ligament regeneration. 
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6 Chapter 6 
 
Stage IV: Development & Characterization of a BMSC-
seeded bFGF-releasing Silk/PLGA-based Biohybrid Scaffold 




In the stages II and III of this study, a biocompatible and biomechanically superior 
silk-based hybrid scaffold system and a bioactive bFGF-delivering PLGA nanofibrous 
scaffold system were developed. In this stage, the outcomes from stage II and III 
would be combined to create the final biofunctional hybrid scaffold that would possess 
superior biomechanical properties as well as deliver biological signals for stem cell 
proliferation and differentiation. These scaffolds would be seeded with bone marrow 
stromal cells and evaluated for tendon/ligament tissue regeneration. 
 
 
6.1 Materials and Methods 
 
6.1.1 Scaffold Fabrication 
 
Knitted silk scaffolds were fabricated using 3 yarns of raw silk fibers and 
degummed using the optimized technique, as described in Chapter 5. The scaffolds 
were then loaded onto the frames of the rotating collector and coated with 1ml of 2% 
aqueous silk solution, as described previously. Two groups of hybrid scaffolds were 
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then fabricated by coating the knitted scaffolds with two types of protein-containing 
electrospun nanofibres: 
 
(i) FGF(+) group being coated with nanofibres electrospun from a blend of bFGF 
and BSA in TRIS, and PLGA in HFIP; and  
(ii) FGF(-) group by electrospinning from a blend of BSA in TRIS (without any 
bFGF) and PLGA in HFIP.  
 
The detailed composition is given in Table 6.1. Electrospinning was performed 
using the set-up described earlier, at a voltage of 11-12 kV and a flow-rate of 0.45-0.50 
ml/hour, with the scaffolds rotating at 60 rpm on the collector, 15 cm from the 
positively-charged spinneret, for 5-6 hours. 
 
 
Table 6.1: Detailed composition of the two groups of protein-containing electrospun 
nanofibres 
 
 FGF(+) FGF(-) 
6.1% PLGA in HFIP 3 ml 3 ml 
0.1% BSA in 5mM TRIS (pH 7.6) 0.467 ml 0.667 ml 
bFGF in 0.1% BSA in 5mM TRIS (pH 7.6) 20 µg in 0.2 ml 0 
 
 
6.1.2 BMSC Seeding on Scaffolds 
 
The hybrid scaffolds were sterilized by exposure to formaldehyde gas for 30 
minutes and UV radiation for 30 minutes on each surface. After degassing the 
scaffolds overnight in the biosafety cabinet, the sterilized scaffolds were placed in 
custom-made chambers (Figure 6.1) and seeded with 1 million rabbit BMSC (P2) on 
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each surface on successive days. The cell-seeded scaffolds were cultured in a complete 
medium, comprising DMEM-high glucose, 5% FBS and 1% penicillin-streptomycin, 
which was replaced twice every week. On the 7th day of culture, the scaffolds were 
rolled up using sterile forceps, and sutured near their ends using sterile degummed silk 
fibers (Figure 6.2). Culture was continued in a 5% CO2 incubator at 37˚C for another 2 
weeks, to allow cells in the different layers of the rolled-up construct grow across the 
layers fusing them 
 
 





Figure 6.2: Rolled-up BMSC-seeded hybrid scaffold 
 
 
6.1.3 Cell Viability and Proliferation Studies 
 
At the end of 2 weeks, viable cells were stained using FDA and visualized under 
the fluorescence microscope (IX71 Inverted Research Microscope, Olympus). The 
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cylindrical construct was sectioned transversely to yield a 1 mm thick disc that was 
visualized under the microscope to study cell distribution in the depth of the scaffold. 
In another scaffold, the nanofibre layers were carefully stripped off from the hybrid 
scaffold to observe the presence and distribution of cells on the silk microfibers of the 
knitted scaffold.  
  
Cell viability and proliferation over the 3 weeks of culture were quantitatively 
studied by Alamar Blue dye reduction assay by incubating the scaffolds (n=3, for each 
group) in 6 ml of complete medium containing 5% Alamar Blue for 3 hours and 
measuring absorbances in a microplate reader (details in Appendix B.3.2). 
 
6.1.4 Soluble Collagen Assay 
 
Total soluble collagen synthesized and secreted into the culture medium by the 
cell-seeded scaffolds (n=3, for each group) was estimated by Sircol® Collagen Assay 
at various time-points (day 7, 14 and 21) over 3 weeks of culture. Culture medium was 
changed 2 days prior to the time-points of the assay so as to allow the measurement of 
soluble collagen freshly produced over 2 days. Results were normalized against the 
amount of collagen produced from the negative controls (BMSC-seeded FGF(-) 
scaffolds) on the 7th day of culture. 
 
6.1.5 Q-RT-PCR Analysis for Expression of Ligament/Tendon-Specific ECM 
Proteins from BMSCs 
 
Fibroblastic differentiation of the seeded BMSC was evaluated by observing for 
upregulation of gene expression for the various tendon/ligament specific ECM proteins 
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(collagen type I, collagen type III, fibronectin and biglycan), as performed in stage III 
of the study. On day 7 and day 14 of culture, one scaffold from each group was 
washed with ice cold PBS, flash-frozen and stored in liquid nitrogen until RNA 
extraction was performed. Total RNA was extracted (as described previously), its 
purity and concentration determined by UV-spectrophotometry and stored at -80°C. Q-
RT-PCR was performed using SYBR-Green chemistry for collagen type I, collagen 
type III, fibronectin and biglycan, using GAPDH and β-actin as reference genes, using 
primer sequences and protocol described in the previous chapter. The amplification 
was performed in duplicates and the results were normalized to the gene expression 
levels on the FGF(-) scaffold on day 7. 
 
6.1.6 Mechanical Testing of Cell-Seeded Constructs 
 
After 3 weeks of culture, cell-seeded biohybrid scaffolds of both groups FGF(+) 
and FGF(-) were tested for their mechanical properties by a tensile tester (Instron 3345 
Tester, Instron, Norwood, MA) using the protocol described earlier. As an additional 
control, 4 unseeded FGF(-) scaffolds were also maintained in similar culture 
conditions and tested for their mechanical properties at the end of 3 weeks. Test 
specimens (n=4) were kept moist by spraying PBS and stretched to failure at a 
crosshead speed of 10 mm/min, without any pretension or preconditioning (Figure 
6.3).  
 
The load (N) and extension (mm) were recorded, and the failure load and stiffness 





Figure 6.3: Mechanical Testing of Biohybrid Scaffolds 
 
 
6.1.7 Data reduction and Statistical analysis 
 
Data were presented as mean ± standard deviation and for pair-wise comparisons, 






6.2.1 Cell Viability and Proliferation Studies 
 
FDA staining at the end of 2 weeks revealed viable cells distributed on both 
nanofibrous surfaces and also in the depths of the scaffold. After removing the 
nanofibrous layers, cells were observed to be proliferating well on the knitted silk 
microfibers (Figure 6.4).  
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Alamar Blue assay revealed that cell viability and proliferation was consistently 
higher on the FGF(+) group than in the control FGF(-) group, with the values being 
30.6%, 31.6% and 23.5% higher at the end of the 1st, 2nd and 3rd week of culture, 
respectively (Figure 6.5). The differences were statistically significant during the first 
2 weeks. 
 
Figure 6.4: FDA staining showing cells proliferating on both nanofibre surfaces (A, B) 
and the knitted microfibres (C) of the hybrid scaffold. Viable cells were also observed 




Figure 6.5: Alamar Blue assay showing consistently higher cell viability and 
proliferation on the FGF(+) group compared to the control FGF(-) group 
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6.2.2 Soluble Collagen Assay 
 
While there was no significant change in the amount of total soluble collagen 
produced by the two groups of cell-seeded scaffolds in the first 2 weeks (with the 
values being slightly lower in the FGF(+) group compared with the FGF(-) group), 
collagen production increased substantially in the 3rd week. At the end of the 3rd week, 
the FGF(+) scaffolds produced 39.1% more collagen than the FGF(-) group (Figure 
6.6). 
 
Figure 6.6: Higher collagen production in from BMSC-seeded FGF(+) scaffolds 




6.2.3 Q-RT-PCR Analysis for Expression of Ligament/Tendon-Specific ECM 
Proteins from BMSCs 
  
On day 7, expression levels of Collagen type I and Collagen type III were down-
regulated in the FGF(+) group compared to the FGF(-) group. However, by day 14, 
expression levels for all four ECM proteins (collagen type I, collagen type III, 
fibronectin and biglycan) were higher in the FGF(+) group. While the expression 
levels of these four proteins decreased from day 7 to day 14 on the FGF(-) scaffolds, 
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they increased on the FGF(+) group during the same period (Figure 6.7). The “tissue 
score” was calculated from the cell proliferation and gene expression data (as 
described earlier in Section 5.3.1), and normalized with respect to values from FGF(-) 
scaffolds on day 7. The BMSC-seeded FGF (+) biohybrid scaffolds showed the 
maximum generation of fibroblastic tissue (Figure 6.8). 
 
   
   
Figure 6.7: Gene expression of Collagen type I, Collagen type III, Fibronectin and 





Figure 6.8: Tissue scores based on Q-RT-PCR and Alamar Blue assay results showing 




6.2.4 Mechanical Testing of Cell-Seeded Constructs 
 
After 3 weeks of culture, the cell-seeded biohybrid nano-microscaffolds were 
observed to have better mechanical properties than the unseeded scaffolds (Figure 6.9). 
The BMSC-seeded FGF(+) scaffolds were 21.1% stronger and 26% stiffer than the 
FGF(-) group; however the differences were not statistically significant (p= 0.06 for 













The BMSC-seeded FGF(+) group of scaffolds performed better in all the tests 
performed. Better cell proliferation, with cells growing not only on the surface of the 
nanofibers, but also on the inner layer of silk microfibers, was observed. Upregulation 
of gene expression for tendon/ligament specific ECM proteins, manifesting as 
increased collagen production and better mechanical properties of the FGF(+) group of 
scaffolds, also confirm that the BMSC-seeded FGF(+) scaffolds were better suited for 
tendon/ligament tissue engineering. 
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6.3.1 Development of biohybrid nano-microscaffold 
 
While the knitted silk scaffold provided mechanical integrity for a prolonged 
period of time, the coating of PLGA nanofibres provided a large biomimetic surface 
for BMSC attachment and, owing to the sustained release of bFGF, their proliferation 
and subsequent differentiation. The nanofibrous PLGA coating is expected to degrade 
over a few weeks and be replaced by newly laid ECM secreted by the differentiating 
stem cells. The knitted silk scaffold would continue to provide mechanical support 
throughout the healing period and allow for maturation and remodelling of the 
neotissue.  
 
6.3.2 Cell viability and proliferation on the biohybrid scaffold 
 
The biohybrid nano-microscaffold provided a favourable substrate for BMSC 
attachment and proliferation, with cells proliferating not only on the nanofibrous layers 
on which they were seeded, but also on the deeper layer of the knitted silk microfibers. 
Cells were also seen populating the central part of the rolled-up hybrid scaffold after 3 
weeks of culture. Sustained release of bioactive bFGF from the FGF(+) scaffolds 
resulted in faster proliferation of the seeded BMSCs followed by their fibroblastic 
differentiation. 
 
6.3.3 BMSC differentiation on the biohybrid scaffolds and generation of tissue 
engineered tendon/ligament 
 
Down-regulated gene expression of the ECM proteins in the BMSCs seeded on 
FGF(+) scaffolds, at the end of the 1st week, but their upregulation by the end of the 
2nd week suggests that the BMSCs were differentiating into fibroblasts. In the absence 
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of bFGF, on the FGF(-) scaffolds, the BMSCs were not very actively proliferating and 
hence the expression levels were never down-regulated. While at the end of 2 weeks, 
increased collagen synthesis was observed only at the transcriptional level, it 
manifested at the protein secretion level by the end of 3 weeks, as evidenced in the 
SirCol assay. Putting together the gene expression and the collagen assay results, it can 
be deduced that the BMSCs seeded on the FGF(+) scaffolds were mainly proliferating 
in the 1st week, started to differentiate into fibroblasts by the end of the 2nd week, 
which became manifest by the end of the 3rd week as significantly higher production of 
collagen. 
 
This is consistent with the results from the previous chapter wherein BMSCs were 
cultured on bFGF-releasing nanofibrous scaffolds alone. While a nanofibrous scaffold 
did provide some signals, possibly due to their biomimetic nanotopography, for the 
seeded stem cells to differentiate, addition of bFGF had a synergistic effect that further 
enhanced stem cell proliferation and differentiation. The bFGF-releasing scaffolds, 
after seeding with bone marrow stem cells, also demonstrated better mechanical 
properties than the control scaffolds without the growth factor. A recent study has 
shown that 3-D polymer scaffolds allowing local delivery of bFGF have been recently 
shown to aid in ligament tissue engineering (216). Not only did the bFGF have a dose-
dependent effect, but it was also influenced by simultaneous mechanical stimulation. 







A novel method for producing a bio-nano-microscaffold was developed by 
electrospinning blend PLGA/bFGF nanofibres, which release bioactive bFGF over a 
week, over the surface and between the loops of the knitted degummed silk scaffold. 
The nanofibers mimicked the natural nano-architecture of tendon extracellular matrix, 
and the released growth factor stimulated initial proliferation and subsequent 
differentiation of the bone marrow stromal cells into fibroblastic cells, that laid a 
collagenous matrix resulting in a stronger and stiffer construct. Thus, the novel 
scaffold was shown to facilitate cell seeding and promote cell proliferation with the 
resulting construct being uniformly populated with mesenchymal stem cells that 
differentiated into a fibroblastic lineage, generating a tendon/ligament analog that 
could be used to repair an injured tendon/ligament. 
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7 Chapter 7 
 
Summary of Results, Discussion and Conclusion 
 
 
7.1 The nano-microfibrous scaffold geometry 
 
Stage I of this study conceptualized a novel nano-microscaffold geometry for 
tissue engineering scaffolds. While earlier work by the research group had shown that 
knitted scaffolds provided a favourable porous architecture for cell proliferation, 
nutrient diffusion and neovascularization after in vivo implantation, they required gel 
systems for cell seeding. This introduced problems of weak gel-scaffold attachment 
and poor nutrient transmission. Coating the knitted PLGA scaffolds with electrospun 
PLGA nanofibrous coatings, inspired by the nanofibrous collagen type I architecture in 
natural extracellular matrix, helped create a novel nano-microscaffold wherein the 
knitted microfibres provided the mechanical integrity while the nanofibers, randomly 
spread over the surface and between the loops of the knitted scaffold, increased the 
surface area and reduced the pore size of the scaffold. 
 
However, for strong and slowly healing tissues like tendon and ligament, PLGA 
was found to be insufficiently strong and too rapidly biodegradable. Changing the 
biomaterial of the knitted scaffold to silkworm silk in Stage II eliminated this 
problem, and the resulting scaffolds possessed the required mechanical properties (a 
failure load of about 60-100 N) with a slow degradation profile (retaining 60% of the 
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original strength at the end of 4 weeks, as compared to PLGA scaffolds that retained 
less than 1% of their original strength after the same period). A comparison of the 
failure load and stiffness of the cell-seeded PLGA- and silk-based nano-microscaffold 
constructs, developed in Stage I and Stage IV of this project respectively, reveals the 
superior mechanical properties of the silk scaffolds (Figure 7.1). The nanofibrous 
PLGA coating is expected to degrade over a few weeks and be replaced by newly laid 
ECM secreted by the differentiating stem cells, while the knitted silk scaffold would 
continue to provide mechanical support throughout the healing period and allow for 
maturation and remodelling of the neotissue. 
 
     
 
Figure 7.1: Significantly superior mechanical properties of the silk-based nano-




7.2 Silk as a biomaterial for knitted and hybrid scaffolds  
 
Stage II of the study introduced silk as the biomaterial for fabricating the knitted 
scaffold. Knitted scaffolds fabricated from 3 yarns of silk fibers, when degummed 
using an optimized technique (boiling in 0.25% Na2CO3 solution with addition of 
0.25% SDS and intermittent ultrasonic agitation), showed improved sericin removal 
and better mechanical properties, that met the required failure load of 60-100N. 
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Biocompatible and mechanically robust nano-microfibrous hybrid scaffolds could be 
created by coating these scaffolds, initially with a 2% silk solution to act as glue, and 
then with nanofibers, using a rotating frame as a collector. The silk coating was shown 
to be stable, as has also been reported in other studies (205, 206). Seeding these hybrid 
scaffolds on both surfaces yielded better cell proliferation than seeding on a single 
surface. Rolling up the cell-seeded hybrid scaffolds after 7 days of culture yielded 
cylindrical constructs that resembled the shape of a tendon graft. Such rolling-up of the 
rectangular knitted scaffolds into cylindrical structures also resulted in an increase of 
the failure load and stiffness of the scaffolds. A cylindrical cross-section is associated 
with a more uniform stress distribution during the failure initiation and growth during 
tensile testing.This is in agreement with another study that reported better mechanical 
properties of braided scaffolds with circular cross-section compared to those with 
rectangular cross-section (24).  
 
 
7.3 BMSC as candidate cells for tendon/ligament tissue engineering 
 
Tendon being relatively hypocellular tissues, it is difficult to obtain tendon cells 
for clinical tissue repair. BMSCs are known to possess the ability of self-renewal and 
differentiation into cells of various mesenchymal lineages. Their ease of collection and 
simplicity of isolation, and excellent properties of attachment, proliferation, and 
synthesis of an ECM rich in collagen type I make them suitable for tissue engineering 
applications (19). Several studies have shown that BMSC could improve tendon 
healing (25, 106) and were better suited for ligament tissue engineering, than cells 
derived from ligaments or skin (23). Results from this study also indicate that BMSC 
differentiated along the lineage of tendon and ligament on the novel scaffolds. 
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However, the use of BMSCs for tendon and ligament tissue engineering has certain 
disadvantages, mostly arising from the limitations in our existing scientific knowledge 
about stem cells, tendon and ligament cells (i) there are no known specific markers for 
rabbit BMSCs, (ii) that the exact environment or the cocktail of signals (physical, 
chemical or biological) that can differentiate stem cells into tendon/ligament 
fibroblasts is still unknown, and finally (iii) there are no known specific markers for 
tendon or ligament cells (71-75). This restricted the present study to characterize 
BMSC differentiation into tendon/ligament lineage only by characterizing the newly 
laid extracellular matrix components in the engineered tissue and an associated loss of 
stemness of the seeded stem cells. 
 
7.4 Effect of nanofibrous substrate on BMSCs function 
 
The nanofibrous coating allowed easy and effective cell seeding via a simple 
method of pipetting the cell-suspension onto the hybrid scaffold, eliminating the need 
of a gel-based cell delivery system. The nanofibers also presented a large biomimetic 
nanotopographic substrate for cell attachment, proliferation and ECM deposition, with 
cells proliferating also on the deeper layer of the knitted silk microfibers and 
populating the central part of the rolled-up hybrid scaffold after 3 weeks of culture.  
 
The seeded BMSCs showed a propensity to differentiate into a tendon/ligament 
lineage, even without any growth or differentiation factor supplementation, in Stages I 
and III of this study. These results suggest that nanotopographic cues from the 




A recent study has proved that a linear alignment of nanofibres causes better cell 
alignment and collagen production from seeded ligament fibroblasts (219). Other 
studies have shown that bFGF aids in stem cell renewal and maintenance of 
multilineage differentiation potential of BMSC in 2-dimensional cultures on tissue 
culture polystyrene (162). This is in contrast with observations from Stage III of this 
study wherein BMSCs seeded on bFGF-releasing nanoscaffolds lost their multilineage 
differentiation potential, after 2 weeks of culture; these findings provide additional 
evidence that the nanofibrous environment plays a crucial role in determining cell 
behaviour and fate. 
 
7.5 Growth factor releasing nanofibres and their effect on BMSC 
proliferation and differentiation 
 
Recent reports on electrospun nanofibrous scaffolds incorporating proteins for 
sustained release (53-56) hypothesise that the incorporated protein is released via a 
combination of degradation of the nanofibres and diffusion across nanopores on the 
nanofibre surface (136, 214, 215). In Stage II of this study, it was shown that the 
incorporated bFGF was released gradually, in a bioactive form, and the release profile 
could be tailored by choosing the appropriate method used to incorporate the growth 
factor in the nanofibres. While blend Group I nanofibers resulted in a faster release 
lasting a week, coaxial Group II nanofibers could sustain the release over a longer 
period of at least 2 weeks. 
 
Inclusion of bFGF in either scaffold group resulted in faster proliferation of the 
seeded BMSCs, followed by their fibroblastic differentiation, particularly on the Group 
I nanofibers, supporting the hypothesis that bFGF release over 1 week was better 
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suitable that a more prolonged release. This effect was observed at bFGF levels in the 
order of pg/ml, as opposed to other in vitro studies where culture media were 
supplemented with 0.1-10 ng/mL of bFGF and replenished twice weekly for the same 
effects (162, 163). This indicates that the combination of physical and biological 
signals from the Group I (+) scaffolds had a synergistic effect, mimicking the ECM of 
injured tendons in both structure and function, by providing a nanofibrous topography 
as well as a week-long supply of bioactive bFGF to the seeded cells. BMSC 
proliferation and subsequent differentiation into fibroblasts and the resultant ECM 
deposition, on the knitted silk scaffold coated with bFGF-releasing PLGA nanofibres, 
resulted in stronger and stiffer constructs in Stage IV of the study. 
 
 
7.6 BMSC differentiation on the biohybrid scaffolds and generation 
of tissue engineered tendon/ligament 
 
Stage IV of the study also demonstrated that bFGF release from the scaffolds 
caused initial proliferation of BMSCs over 1 week, followed by their differentiation 
into fibroblasts that manifested at the gene-expression stage by 2 weeks and protein 
secretion stage by the end of 3 weeks. This is in consistency with the results from the 
Stage II wherein BMSCs were cultured on bFGF-releasing nanofibrous scaffolds 
demonstrated better proliferation and differentiation. The released bFGF and the 
biomimetic nanotopography of the nanofibrous scaffolds likely exert a synergistic 
effect on the proliferation and differentiation of seeded BMSCs. Initial cell 
proliferation leading to high confluency presumably caused contact inhibition and 
initiation of cell differentiation. The initial proliferative phase is beneficial as it would 
permit seeding of the scaffolds with a lower cell density, and would also ensure that 
the scaffold gets uniformly populated with the cells, before they start to differentiate. 
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This is important as the initial distribution of cells within the scaffold determines the 
distribution of neotissue formed within engineered constructs (222). Consistent with 
BMSC differentiation and increased collagenous ECM deposition on the bFGF-
releasing hybrid scaffolds, these scaffolds also demonstrated better mechanical 
properties than the control scaffolds without the bFGF, making them more suitable for 




A novel method for producing a nano-microscaffold was developed in this stage 
of the PhD project. Electrospinning PLGA nanofibres over the surface and between the 
loops of the knitted PLGA scaffold increased the surface area and reduced the pore-
size of the knitted scaffold, thereby eliminating the need of cell-delivery by fibrin gel. 
The nanofibers also mimic the natural nano-architecture of tendon extracellular matrix, 
which promoted the functional capability of the bone marrow stromal cells to secrete a 
tendon/ligament specific matrix. Thus, the novel scaffold is shown to facilitate cell 
seeding, promote cell proliferation and function, showing promise in tissue 
engineering of tendon/ligament. 
 
Since PLGA was found to be too rapidly biodegradable, knitted scaffolds 
fabricated from 3 yarns of silkworm silk fibers were chosen instead. The degumming 
technique was optimized to improve sericin removal while retaining the mechanical 
properties of silk fibroin scaffold. Degumming by boiling in 0.25% Na2CO3 solution 
containing 0.25% SDS with intermittent ultrasonic agitation allowed the scaffold to 
retain the original failure load of native silk. After coating with nanofibers, using a 2% 
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silk solution as glue and a rotating frame as a collector, biocompatible and 
mechanically robust nano-microfibrous hybrid scaffolds could be created. Seeding 
these hybrid scaffolds on both surfaces and rolling up the cell-seeded hybrid scaffolds 
after 7 days of culture could yield cylindrical analogues that resembled the shape of a 
tendon/ligament graft.  
 
Polymeric nanoscaffolds capable of continued release of bioactive growth factors, 
with different release profiles and surface hydrophilicity, were also developed in the 
study. It was found that both scaffolds were composed of smooth continuous 
nanofibers, with proteins successfully incorporated in them, randomly dispersed in 
Group I and as a central core within Group II nanofibres. It was shown that between 
Group I and Group II scaffolds, Group I (+) scaffolds released the incorporated bFGF 
in a bioactive form over 1 week, were more hydrophilic, favoured BMSC attachment 
and, particularly, proliferation and differentiation into a tendon/ligament fibroblastic 
lineage. 
 
These blend PLGA/bFGF nanofibres were a suitable candidate for coating the 
mechanically strong degummed knitted silk scaffold to produce a hybrid “bio-nano-
microscaffold”. The nanofibers mimicked the natural nano-architecture of tendon 
extracellular matrix and the released growth factor stimulated initial proliferation and 
subsequent differentiation of the bone marrow stromal cells into fibroblastic cells, 
which laid down a collagenous matrix resulting in a stronger and stiffer construct. 
Thus, the novel scaffold was shown to facilitate cell seeding, promote cell proliferation 
with the resulting construct being uniformly populated with bone marrow derived 
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mesenchymal stem cells, which differentiated into a fibroblastic lineage, generating a 
tendon/ligament analog that could be used to repair an injured tendon/ligament. 
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8 Chapter 8 
 
Recommendation for Future Work 
 
 
This study used only a single growth factor in a single dose, which cannot be 
claimed to be the optimal condition for inducing fibroblastic differentiation of bone 
marrow derived mesenchymal stem cells. Cell behavior and fate is not only affected by 
the concentration and duration of exposure to a growth factor, but it is also likely that a 
combination of growth and differentiation factors play a role. Future studies involving 
use of multiple growth factors, particularly PDGF-BB and TGF-β in addition to bFGF, 
wherein the dose, duration and temporal profile of release are varied, could help in 
further optimizing the differentiation pathway. The exact reasons behind the different 
behavior of BMSCs on the two types of bFGF-releasing nanofibers, where the only 
observed differences were in the hydrophilicity and bFGF release profile, were also 
not clearly understood. In depth characterization of the nanofibers, particularly of their 
surface properties such as surface chemistry, charge and topography, as well as 
elucidation of the mechanism of growth factor release, which have not been 
investigated in this study, would be useful. 
 
The effect of simultaneous mechanical stimulation in addition to local sustained 
delivery of bFGF has been recently shown to aid in ligament tissue engineering (216). 
Simultaneous application of cyclic mechanical stimulation through a bioreactor could 




Limitations in the current scientific knowledge about specific cellular markers for 
BMSCs and tendon/ligament cells in the New Zealand White Rabbit species made it 
difficult to verify the differentiation of BMSCs in this study. This could be 
demonstrated only indirectly through loss of multipotency of the BMSCs. Use of 
human BMSCs could overcome this problem, as a multitude of specific markers are 
known for these cells. Moreover, since the human genome is completely sequenced, it 
would also be possible to study the gene expression, in the tissue engineered construct, 
of various tendon/ligament specific proteins, the genetic code for which are presently 
not known in rabbits. Moreover, BMSCs from rabbits and human could respond to 
different dose and/or duration of various stimuli. Thus, the use of human BMSCs 
would also make it possible to evaluate and optimize the scaffold for the ultimate aim 
of human tissue engineering applications. 
 
A successful tissue engineering strategy would be one that could eventually be 
translated and applied clinically, and success in animal models is an important 
prerequisite. Though the in vitro cell culture assays and biomechanical tests in the 
current study provide key information about the tissue-engineered tendon, 
experimental testing in an appropriate animal model is essential for its critical 
evaluation and optimization. Thus a systematic animal study is recommended to 
validate the in vitro results from this study. The tissue engineering tendon developed in 
this study could be evaluated for their efficacy in repairing surgical defects created in 
the central one-third of the patellar tendons of New Zealand White Rabbits, the animal 
species also used in the current study to obtain the BMSC. When performed with 
appropriate controls (bFGF-loaded biohybrid scaffolds alone, or BMSC-seeded hybrid 
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scaffolds without any bFGF), this study could prove that BMSC-seeded and bFGF-
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B. Appendix B 
 
 
B.1    Design of culture chamber 
 
Culture chambers having six wells with dimensions of 25mm x 45 mm x 10mm 
(depth) were designed (Figure B.1) and fabricated from transparent Polycarbonate 
blocks of dimensions 125mm x 125 mm x 20 mm (depth). The chambers are 
autoclavable and covered with sterilized lids of 120 mm × 120 mm square petri-dishes 
(Greiner) before use for tissue culture. 
 
 




B.2    Design of K wire frame 
 
A 1 mm diameter Kirschner’s wire was cut into 100 mm pieces, and bent at right 
angles, into a 20 mm x 40mm U-shaped frame, as shown in Figure B.2. Knitted 
scaffolds of dimensions 20mm x 40 mm were kept uncurled on these wire frames and 
nanofibers were electrospun on their surfaces. 
 
 
Figure B.2: Design and fabrication of U-shaped K-wire frames from straight K-wires 
 
 
B.3    Cell Viability/Proliferation Assays 
 
Cell viability and proliferation on the various scaffolds in this study has been 
studied using either metabolic assays (MTS Assay and Alamar Blue Assay) or by 
DNA quantification (PicoGreen Assay). 
 
B.3.1 MTS Assay (CellTitre96)  
 
The CellTiter96® AQueous One Solution Cell Proliferation Assay (Promega 
Corporation, Madison, WI, USA) is a cytotoxic colorimetric method for determining 
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the number of viable cells in proliferation or cytotoxicity assays. Viable cells react 
with the tetrazolium compound to produce a coloured formazan product that is soluble 
in tissue culture medium. This conversion is presumably accomplished by NADPH or 
NADH produced by dehydrogenase enzymes in metabolically active cells. 
 
160µl of the reagent was pipetted into each well of the culture chamber containing 
the cell-scaffold constructs in 800µl of fresh culture medium. After incubation for 1-4 
hours at 37°C in a humidified, 5% CO2 atmosphere, assays were performed by 
recording absorbance at 490nm with a 96 well plate reader. The quantity of formazan 
product as measured by the amount of 490nm absorbance is directly proportional to 
the number of viable and metabolically cells in culture. A reference wavelength of 
656nm was used for correction of background contributed by excess cell debris, 
fingerprints and other nonspecific absorbance. 
  
Since MTS is cytotoxic, the cell-seeded scaffolds had to be sacrificesd after assay. 
To perform a longitudinal study of cell proliferation on the same set od scaffolds, a 
non-cytotoxic cell proliferation assay like Alamar Blue Assay was adopted. 
 
B.3.2 Alamar Blue Assay 
 
As with MTS, Alamar Blue also monitors the reducing environment of the 
proliferating cell. It is composed of a blue dye, called resazurin that is reduced by the 
metabolic products of viable cells to form a fluorescent red dye called resorufin. The 
amount of resazurin can be measured at 600nm absorbance wavelength while resorufin 
at 570nm wavelength. The percentage reduction of resazurin to resorufin, calculated 
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with compensation for the culture medium background absorbance, reflects cell 
viability.  
 
A 5-10 % (v/v) Alamar Blue solution in culture medium (DMEM containing 5-
10% FBS, as used for cell culture) was prepared. The cell seeded scaffolds were 
submerged in this solution for 3 hours at 37°C in a humidified, 5% CO2 atmosphere. 
For background adjustment, about 5 ml of the Alamar Blue medium was kept under 
the same conditions in a Petri dish (without any cells). Assays were performed by 
recording absorbance at 570nm and 600nm using a 96-well plate reader. Care was 
taken throughout the assay to minimize exposure of Alamar Blue to light. 
 
 The percentage reduction is calculated by the following formula: 
 
( )( ) ( )( )








AoxAox     …………………….1 
 
where 
( )1λε redx  = 155,677 (Molar extinction coefficient of reduced Alamar Blue at 570nm); 
( )2λε red  = 14,652 (Molar extinction coefficient of reduced Alamar Blue at 600nm); 
( )1λε ox  = 80,586 (Molar extinction coefficient of oxidized Alamar Blue at 570nm); 
( )2λε ox  = 117, 216 ((Molar extinction coefficient of oxidized Alamar Blue at 600nm); 
( )1λA  = Absorbance of tests wells at 570nm; 
( )2λA  = Absorbance of tests wells at 600nm; 
( )1'λA  = Absorbance of negative control wells (medium plus Alamar Blue but without 
cells) at 570nm; 
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( )2'λA  = Absorbance of negative control wells medium plus Alamar Blue but without 
cells) at 600nm. 
  
 Another formula that allows for correction due to presence of oxidized and 
partially reduced Alamar Blue in the culture medium has been reported to be more 
accurate. For this method, an additional sample comprising culture medium alone 
(without Alamar Blue) is incubated under the same conditions and its absorbance 
recorded along with other samples/controls. Subtracting the absorbance values of the 
media blank from the absorbance values of the test samples, at each wavelength (570 
and 600nm) yields: 
 
A570 = Absorbance of Reduced form at 570nm, and 
A600 = Absorbance of Reduced form at 600nm 
 
Similarly, subtracting the absorbance values of media only from the absorbance 
values of Alamar Blue in media, at each wavelength (570 and 600nm) yields:  
 
AO570 = Absorbance of Oxidized Alamar Blue at 570nm, and  
AO600 = Absorbance of Oxidized Alamar Blue at 600nm. 
 
Correction Factor, R0 = AO570 / AO600 
 
The corrected percentage reduction of Alamar Blue is obtained as: 
 
Corrected % Reduction, AR570= [A570 - (A600 * R0)] * 100%         .......................2 
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Being soluble, stable in culture medium and nontoxic, Alamar Blue permits an 
easy and non-destructive assay for continuous monitoring of cultured cells. However, 
the use of metabolic assays to study cell proliferation rates assumes that all the cells 
are in the similar metabolic state. This assumption would not be valid in the current 
study as the cells have been stimulated using a growth factor, and metabolic rates of 
proliferating stem cells and their differentiated progeny are expected to be different. In 
addition, use of metabolic assays depends on dye diffusion across the cell. Additional 
diffusion constraints that are encountered in a 3D scaffold system can also diminish 
the accuracy of the metabolic assay results. These shortcomings can be overcome by 
DNA Quantitation assays that measure the absolute or relative quantity of DNA 
present in a tissue sample and thus reflect cell number rather than their metabolic rate. 
 
B.3.3 PicoGreen Assay 
 
PicoGreen assay is a colorimetric assay that employs an ultrasensitive fluorescent 
nucleic acid stain for quantitating double-stranded DNA (dsDNA) in solution, thereby 
determining the cell number and evaluating cell proliferation. The kit used in this study 
(Quant-iT™ PicoGreen® dsDNA Kit, Molecular Probes, Invitrogen Corporation) has 
a sensitivity of 25 pg/mL of dsDNA using a standard spectrofluorometer.  
 
To prepare for this assay the cell-seeded scaffold was digested, and the cells in the 
scaffold disrupted (using freeze-thawing, lysis buffers and homogenising) so that their 
DNA was released into solution. PicoGreen dye specifically binds to dsDNA in the 
solution and emits fluorescence at a wavelength of 520nm. After background 
correction using a blank sample and comparing against a standard curve of known 
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DNA concentrations, the amount of DNA present in a sample was determined and 
correlated to cell proliferation. 
 
 
B.4     Live Cell Staining: FDA and CMFDA 
 
Fluorescein diacetate (FDA, Molecular Probes, Invitrogen Corporation, USA) is a 
cell-permeant dye that forms fluorescein by intracellular hydrolysis by mitochondrial 
enzymes, thus labeling only the live cells in a population. After rinsing off the cell-
culture medium, the cells are stained with a 5μg/ml solution of FDA in 1X  PBS for 10 
minutes at room temperature. The samples are then rinsed with 1X  PBS, kept on ice 
and visualized under a fluorescence microscope A/E of  488/517 nm to view the green 
fluorescing live cells. However, fluorescein rapidly leaks from cells, with 95% being 
effluxed in 1 hour. 
  
5-chloromethyl fluorescein diacetate (CMFDA, Cell Tracker Green, Molecular 
Probes, Invitrogen Corporation, USA) is a derivative of FDA that freely diffuses 
through the membranes of live cells. It is also essentially colourless and non-
fluorescent until it is cleaved by intracellular esterases to yield highly fluorescent 5-
chloromethylfluorescein, which can then react with thiols on proteins and peptides to 
form aldehyde-fixable conjugates. After rinsing off the cell-culture medium, the cells 
are stained with CMFDA (10μM) in serum-free DMEM for 30 minutes at 37 °C. The 
medium is again changed to fresh DMEM, and the samples incubated for another 30-
60 min in the CO2 incubator at 37˚C. The scaffolds we re then rinsed with PBS and 
visualized at A/E of 492/517nm. Cells stained with CMFDA remain fluorescent and 
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B.5     Sircol® Collagen Assay 
 
The Sircol® Assay (Biocolor Ltd, Northern Ireland) is a quantitative dye‐binding 
assay for acid‐soluble collagens released into culture medium by mammalian cells 
during in vitro culture. The Sircol Dye Reagent, Picrosirius Red, selectively binds to 
the [Gly-X-Y]n tripeptide sequences in triple-helical collagens type I to V, crosslinks 
and precipitates them. From this precipitate, the dye is released under strong alkaline 
conditions and its absorbance measured at 540nm. After comparison with collagen 
standards the amount of collagen in the sample is estimated. 
 
Presence of FBS in the culture medium at concentrations above 5% is known to 
interfere with the assay. Hence, 2 days before the assay, the cell-seeded scaffolds are 
cultured in DMEM with 5% FBS. This also ensures that only freshly synthesized 
soluble collagen is assayed. 100µL of the medium is mixed with 1ml of Sircol dye 
reagent for 30 minutes at room temperature. The precipitate formed after centrifuging 
at 10,000g for 10 minutes is suspended in 1ml of Alkali Reagent. 100µL of this 
solution is pipetted into triplicate wells of a 96-well plate and their absorbance 
measured at 540nm in a Microplate Reader (TECAN Microplate Reader, Magellan 
Instrument Control and Data Analysis Software). The concentration of collagen, thus 
obtained, is then multiplied with the total volume of medium collected from the 
respective scaffolds to give an estimate of the total amount of collagen secreted per 
scaffold over 2 days. 
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B.6     Blyscan® Glycosaminoglycan Assay 
 
The Blyscan® Glycosaminoglycan Assay (Biocolor Ltd, Northern Ireland) is a 
quantitative dye binding assay for solubilized sulfated proteoglycans (PG) and 
glycosaminoglycans (GAG). The assay is based on the specific binding of the cationic 
dye, 1,9-dimethyl methylene blue (DMBB), to sulfated GAGs and PGs. 
 
Culture media is changed 2 days prior to the day of assay to estimate the total 
amount of GAG secreted by the cell-seeded scaffolds in 2 days. After mixing 100µL of 
the culture medium with 1ml of Blyscan dye reagent for 30 minutes at room 
temperature, the solution is centrifuged at 10,000g for 10 minutes. The precipitate is 
suspended in 1ml of Blyscan Dye Dissociation reagent and 100µL of this solution is 
pipetted into triplicate wells of a 96-well plate. Based on absorbance at 656nm, with 
550nm as the reference wavelength, read using a Microplate Reader (TECAN 
Microplate Reader, Magellan Instrument Control and Data Analysis Software), and 
comparing against a standard curve using chondroitin 4-sulfate standards, the 
concentration of GAGs in the culture medium was estimated. The total amount of 
GAGs secreted per scaffold over 2 days is then calculated by multiplying with GAG 
concentration with the total volume of medium collected from the respective scaffolds. 
 
B.7     Proliferation of Rabbit BMSCs at different FBS and bFGF 
concentrations in Culture Medium 
 
Since FBS is a rich source of a multitude of growth factors including bFGF (300 
pg/mL), DMEM supplemented with a high percentage of FBS is likely to contain a 
high concentration of bFGF that would confound the effect of bFGF released from the 
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scaffolds. To address this problem, a optimization study of BMSC culture using 
growth media supplemented with various concentrations of FBS and bFGF, with an 
aim to establish serum-free or serum-poor culture conditions for BMSC was 
conducted. 
 
When BMSCs were cultured in DMEM-HG with 10% FBS, supplemented with 
varying concentrations of bFGF (0, 0.1, 1 and 10 ng/ml), cell proliferation was 
observed over the 20 days of culture. However, on any particular time-point, there was 
no significant difference in the cell proliferation (as determined by Alamar Blue assay) 
between the various groups (Figure B.3). 
 
 
Figure B.3: BMSC proliferation on media containing 10% FBS and supplemented with 
varying concentrations of bFGF. At 10% FBS, bFGF supplementation failed to show 
any change in BMSC proliferation rate 
 
 
These results suggest that the media containing 10% FBS confound the effect of 




To determine the optimum serum supplementation that allows BMSCs to 
proliferate normally and also permits supplemented bFGF to cause discernable effects 
on cell proliferation, rabbit BMSCs were seeded in triplicate wells of a 96-well plate 
and cultured in media containing varying concentrations of FBS (0, 1, 5 and 10%) and 
bFGF (a:0, b:0.1, c:1 and d:10 ng/ml). 5,000 BMSCs (P2) were seeded per well, and 
cultured for 7 days with the medium being replaced every 2 days.  
 










Figure B.4: BMSC proliferation on media containing varying concentrations of FBS 
(0, 1, 5 and 10%) and bFGF (a: 0, b: 0.1, c: 1 and d: 10 ng/ml). At 5% FBS, maximal 
increase in cell proliferation rate was observed at 0.1 ng/ml bFGF supplementation 
 
 
Alamar Blue results indicated that serum-free (0%) conditions were not conducive 
for BMSC culture; while 10% FBS resulted in the best cell proliferation rates, 
increasing bFGF supplementation in 10% FBS resulted in declining proliferation 
(Figure B.4). On the other hand, 0.1ng/ml supplementation of 5% FBS showed the 
most significant increase in the cell proliferation rate. A notable effect that was 
observed at all FBS levels was that cell proliferation was better at 0.1ng/ml bFGF 
supplementation than at 10ng/ml. 
